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The Forkhead box A2 transcription factor (Foxa2/HNF-3β) has been 
shown to be a key regulator of genes involved in the maintenance of glucose 
and lipid homeostasis in the liver, and is constitutively inactivated in several 
hyperinsulinemic/obese mouse models, thereby enhancing their metabolic 
phenotypes.  Foxa2 is activated under fasting conditions, but is inhibited by 
insulin signaling via PI3K/Akt in a phosphorylation-dependent manner, which 
results in its nuclear exclusion.  However, the mechanism and relative 
importance of nuclear export have not yet been elucidated.  In addition, the 
existence and potential role of insulin-dependent regulation of Foxa2 have not 
been studied in other tissues where it is expressed, such as the gut, lung, and 
hypothalamus.   
Here we further investigate the regulation of Foxa2 by insulin and the 
mechanism and relevance of its nuclear exclusion.  We demonstrate that 
differential regulation of Foxa2 exists in different mouse models, that this 
variability is dependent on circulating insulin levels, and that Foxa2 activity 
correlates with metabolic function.  We further show that Foxa2 contains a 
functional nuclear export signal and is excluded from the nucleus via a CRM1-
 
     dependent pathway in response to insulin signaling.  Our data provide direct 
     evidence that nuclear export-defective Foxa2 is phosphorylated and inactivated 
     by insulin both in vitro and in vivo, suggesting that phosphorylation itself is the 
     main regulatory event regulating the activity of Foxa2, and not nuclear 
     exclusion per se.  Finally, we provide evidence for and physiological 
     consequences of insulin-dependent inactivation of Foxa2 in two other 
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Globally, diabetes is ranked by the world health organization as the fifth 
leading cause of death (1).  Using data from 2003, the international diabetes 
foundation estimated that 194 million people, ages 20-79 (roughly 5% of the 
world’s population) have diabetes.  An additional 8% show signs of impaired 
glucose tolerance, a high risk factor for the development of type 2 diabetes (2).  
With the death rate from diabetes mellitus having increased by 45% from 1987-
2002, it is imperative that we understand the underlying causes of this complex 
disorder (3). 
Originally described as nonketotic, or non-insulin-dependent diabetes, 
type 2 diabetes mellitus is a complex disease characterized by abnormal glucose 
tolerance and hyperglycemia due to increased insulin resistance in combination 
with relative insulin deficiency (4).  While it has become clear that obesity (5, 6), 
fat distribution (5), and physical inactivity (6) are all risk factors correlated with 
the development of type 2 diabetes, the molecular mechanisms connecting 
these risk factors to the onset of insulin resistance and relative insulin 
deficiency resulting in type 2 diabetes remain unclear.     
 Understanding the pathology of diabetes requires an intricate knowledge 
of the cellular signaling associated with insulin.  In mammals, insulin is the 
main hormone regulating the maintenance of glucose homeostasis.  In fasting 
states there exists a balance between glucose production and tissue uptake and 
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utilization, such that blood glucose levels are maintained within a narrow range.  
In response to increased glucose levels, such as after a meal, insulin secreted 
from pancreatic beta cells induces the uptake of glucose into peripheral tissues 
and inhibits endogenous glucose production, thus restoring and maintaining 
normoglycemia.  Conversely, in fasting states when glucose and insulin levels 
are low, and glucagon levels are increased, this suppression is relieved. (7) 
The liver plays an essential role in this process of glucose homeostasis 
and is a main target of insulin action.  When insulin levels are high, hepatic 
programs of gluconeogenesis, glycogenolysis and fatty acid beta oxidation are 
suppressed (8).  Though the effects of insulin are pleitropic and complex, this 
suppression occurs in large part through the transcriptional inhibition of key 
rate limiting enzymes in these pathways (9).  To this end, the forkhead box A2 
transcription factor (Foxa2/HNF3β) has been shown to be a key regulator of 
genes involved in the maintenance of glucose and lipid homeostasis in the liver 
(10, 11). 
The forkhead superfamily of transcription factors, of which Foxa2 is a 
member, is defined by a conserved, 110-amino acid winged-helix DNA binding 
domain (12).  Currently more than 100 members have been assigned to this 
gene family in species ranging from yeast to humans (13).  However, there is 
very little sequence conservation outside of the winged helix domain in many 
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of these genes, where even subtle changes have been seen to affect DNA 
binding (13, 14).  Consequently the different forkhead family members have 
been found to affect a varied array of target genes with functions ranging from 
regulation of development in a wide variety of tissues (15, 16), to DNA repair 
(17), and apoptosis (18).  Some forkhead proteins have been shown to act as 
transcriptional activators while others act as repressors.   
The hepatocyte nuclear factor 3 (HNF-3)/forkhead family of 
transcription factors in mammals includes three genes designated Foxa1 (HNF-
3α), Foxa2 (HNF-3β) and Foxa3 (HNF-3γ), which have overlapping patterns of 
tissue expression, including gut, central nervous system, neuroendocrine cells, 
and lung (14, 19).  Originally identified as liver-enriched proteins that bind to 
specific sequences in the transthyretin (TTR) and alpha1-antitrypsin (α1-AT) 
promoters and activate their transcription (20), the HNF-3 (Foxa) proteins are 
generally considered to be the founders of the forkhead family (identified at the 
same time as the drosophila fork head protein) (14).   
Foxa proteins have subsequently been shown to be critical regulators of 
development, growth and metabolism in worms, flies and mammals.  Reduced 
levels of pha-4, the Foxa homologue in worms, leads to developmental arrest 
and, post-embryonically, inhibits the ability of the organism to respond to 
dietary manipulations (21).  Simultaneous knock-down of daf-16, the Foxo 
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homologue, had an additive effect on dauer recovery in worms, suggesting that 
these two factors function in parallel pathways.  Furthermore, dietary 
restriction leads to increased expression of pha-4, which activates genes that 
protect against oxidative damage (e.g. superoxide dismutase) (22). 
Mouse genetic studies have also revealed important roles for murine 
Foxa genes in development and metabolism. In livers of adult mice, Foxa2 
activity has been shown to mediate fasting responses, including fatty acid 
oxidation, ketogenesis, and increased VLDL and HDL secretion, by activating 
gene expression of key enzymes of these pathways (10, 23, 24).  
The DNA-binding domain of Foxa3 has been crystallized bound to its 
target DNA sequence, revealing monomeric DNA-binding and a novel 
“winged helix” motif (25).  The extent and pattern of sequence conservation in 
the DNA-binding regions of known members of the forkhead family indicates 
that all forkhead family members share this basic structural domain.  In 
particular, this is assumed to be the case for Foxa1 and Foxa2 which share 95% 
and 90% sequence identity in this region, respectively.   
Interestingly, it was also observed that this Foxa DNA binding domain is 
similar in structure to that of the linker histone H5 (25).  However, in contrast 
to linker histones that compact DNA in chromatin and repress gene 
expression, FoxA proteins are associated with transcriptionally active 
chromatin and may decompact DNA from the nucleosome (26, 27).  
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Additionally, this high affinity DNA-binding site in combination with C-
terminal regions mediating interaction with histones H3 and H4 have been 
shown to enable Foxas to act as pioneer transcription factors, which are able to 
decompact DNA from nucleosomes without ATP-dependent enzymes (26).   
While Foxa proteins share very high sequence homology within the 
DNA binding domain (as well as a suggested common consensus sequence for 
DNA binding (28)), Foxa proteins are not entirely redundant in function.  
Outside of this conserved region, Foxa1 and Foxa2 are only 39% identical, 
with Foxa3 being even more distinct (14).  Accordingly, these differences are 
reflected in phenotypes of knock-out mice.  Mice homozygous for a null 
mutation in Foxa2 exhibit an embryonic lethal phenotype, lack a notochord 
and exhibit defects in foregut and neural tube development, while Foxa3-
deficient mice develop normally (29-31).  Mice lacking Foxa1 expression 
develop neonatal persistent hypoglycemia, hormonal insufficiencies, pancreatic 
alpha- and beta-cell dysfunction and die between postnatal days 2 and 14 (32, 
33).   
The sequence divergence among the Foxa proteins also allows for 
unique posttranslational modifications and differential DNA and protein 
interactions.  Previous work in our lab has shown that Foxa2, but not Foxa1 or 
Foxa3, is negatively regulated by insulin in the liver.  In unstimulated, or fasting 
states, Foxa2 is consistently observed in the nucleus, and only extensive 
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mutation of the DNA-binding/nuclear localization domains alters this cellular 
distribution (10, 11, 19, 20, 34, 35).  However, in response to increasing 
concentrations of insulin in vitro and in vivo in perfused mouse liver, Foxa2 
shows dose-dependent nuclear exclusion, which corresponds with its 
phosphorylation (10, 36).  This phosphorylation has been mapped to threonine 
156 in a conserved AKT site, and a single point mutation of T156 to alanine 
(T156A) alone abolishes insulin-induced nuclear exclusion.  Insulin has also 
been shown to inhibit transactivation by Foxa2, both in reporter assays, as well 
as in ad libitum fed and hyperinsulinemic mice.  Likewise, this transcriptional 
inactivation is completely alleviated by T156A mutation.  Thus, Foxa2T156A is 
a constitutively active, constitutively nuclear Foxa2 variant. 
Cotransfection of wildtype or constitutively active (but not dominant 
negative) AKT in reporter assays was shown to mimic the effects of insulin on 
Foxa2 transactivation, while inhibition of PI3-kinase signaling repressed the 
effects of insulin.  Direct phosphorylation of Foxa2 by AKT was further 
supported by in vitro kinase assays,  in addition to coimmunoprecipitation 
experiments, in which wildtype Foxa2, but not Foxa2 T156A or R153A (a 
Foxa2 mutant that is unable to bind AKT) can be immunoprecipitated with 
and phosphorylated by AKT (36, 37).  Together these data have led to the 





Figure 1.  Model illustrating the regulation of Foxa2 by insulin.  Insulin binds to and activates the 
insulin receptor (IR), which triggers autophosphorylation and the recruitment and phosphorylation of 
insulin receptor substrate (IRS) adaptor proteins.  These proteins transmit the insulin signal by 
activating PI3-kinase, which phosphorylates phosphatidylinositol (4,5) bisphosphate (PIP2) and 
catalyzes the formation of PIP3.  This leads to the phosphorylation and activation of protein kinase B 
(AKT) by PDK1 and the mTORC2 complex.  AKT, which has been found in the nucleus upon 
activation, phosphorylates Foxa2 at T156, which is then excluded from the nucleus and thus 
inactivate.  Insulin withdrawal allows reentry of Foxa2 into the nucleus, presumably through 
regulation of a phosphatase. 
 
Several studies have been carried out to elucidate the function of 
different domains of Foxa2, and are summarized in Figure 2.  In addition to its 
winged helix DNA-binding domain, the regions flanking the C-terminal, and 
partially overlapping the N-terminal end of this domain have been shown to be 
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required for nuclear localization.  Four additional conserved regions have been 
identified and together form two transactivation domains (at the amino and 
carboxy terminal), which are important for target gene discrimination and 
activation (34, 38).  More recently the AKT phosphorylation site and a PGC1β-
interaction domain have been described (24, 36). 
 
 
Figure 2.  Schematic depiction of Foxa2 showing known domains.   II-V, transactivation domains; p, 
phosphorylation site; NLS, nuclear localization signal (N- or C-terminal of the DNA binding 
domain); DBD, DNA binding domain; PGC1β, PGC1β interaction domain. 
 
The importance of the phosphorylation site has been further analyzed in 
mouse models of type 2 diabetes.  In hyperinsulinemic/obese mice, Foxa2 (but 
not Foxo1) is permanently excluded from the nucleus and its inactivation 
contributes to the development of hepatic steatosis and insulin resistance.  This 
has been demonstrated by re-expression of constitutive active Foxa2 
(Foxa2T156A) in livers of obese mouse models that led to increased Fatty acid 
oxidation, increased VLDL secretion, reduced hepatic TAG content and 
increased insulin sensitivity and normalization of blood glucose levels (10).   
The differential regulation of Foxo1 and Foxa2 in insulin resistant states 
is somewhat counterintuitive, since both have been shown to be inhibited by 
insulin signaling through the PI3-kinase pathway.  However, this can be 
explained by increased sensitivity of Foxa2.  Knockdown of IRS2 alone was 
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able to abolish nuclear export of Foxo1, however knockdown of both IRS1 
and IRS2 was required for inhibition of nuclear export of Foxa2 (10).  It has 
been shown that there is decreased expression of IRS2 in insulin-resistance 
states, while IRS1 levels remain unchanged (39).    This provides an enticing 
explanation for the mixed insulin resistance observed in many models of type 2 
diabetes, and suggests a mechanism whereby the inhibition of 
gluoconeogenesis is lost, but the inhibition of fatty acid oxidation is not.  
As evidenced by Foxo1, the negative regulation of forkhead 
transcription factors by nutritional or stress signals is not unique to Foxa 
proteins.  PI3-kinase/Akt signaling in the nematode Caenorhabditis elegans, 
suppresses the function of DAF-16, a transcription factor that belongs to the 
Foxo branch of the forkhead/winged-helix family (40). Mutations in the 
insulin/Igf-1 receptor homologue (daf-2) (41, 42), the catalytic subunit of PI3-
kinase (age-1) (43), or Akt (akt1 and akt2) (44), result in increased longevity and 
constitutive dauer formation, a stage of developmental arrest and reduced 
metabolic activity that enhances survival during periods of food deprivation 
and other environmental stresses. In each case, mutation of daf-16 restored 
normal life span and prevented entry into dauer stage.  
 In mammals, this regulation has also been described for Fkhr (Foxo1), 
Fkhrl1 (Foxo3), and AFX (Foxo4) (18, 45-47).  Foxo-1 can be phosphorylated 
by Pkb/Akt at multiple sites causing repression of transcriptional activity of 
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target genes such as insulin growth factor binding protein 1 (Igfbp-1), glucose-
6-phospatase and phosphoenolpyruvate carboxykinase (48, 49).  Similar to 
Foxa2, this regulation has been shown to occur, at least in part, by nuclear 
exclusion, although recent findings suggest that additional mechanisms are 
involved (50). At the moment it is unclear whether nuclear export is the key 
mechanism regulating Foxo transcription factors or whether other nucleus 
specific regulatory pathways are involved in the regulation of this factor as well.  
The constitutive inactivation of Foxa2 by insulin, in addition to the 
beneficial effects of constitutively active Foxa2 in mouse models of obesity 
make understanding the molecular mechanisms of its regulation of great 
scientific and potentially therapeutic interest.  While it is clear that 
phosphorylation is necessary for nuclear exclusion of Foxa2, the mechanism 
and importance of nuclear exclusion in the inactivation of Foxa2 by insulin has 
not previously been investigated.  Here, we explore the molecular mechanisms 
controlling nuclear exclusion of Foxa2 in response to insulin signaling, and its 




CHAPTER 1:  Genetic Strain variations modulate Foxa2 activity 
1.1  Effect of insulin on Foxa2 in hepatocytes from diabetic mice 
We have shown that nuclear exclusion of Foxa2 closely correlates with 
insulin levels, both in wild-type C57Bl/6 and in hyperinsulinemic mouse 
models.   Nonetheless, there was initially some disagreement in the literature 
over this point (11).  While wildtype C57Bl/6 mice have fasting glucose levels 
around 0.3 ng/mL (going up to ~3 ng/mL in fed mice) ob/ob, db/db and HF 
mice are all hyperinsulinemic even after a fast, with plasma insulin 
concentrations ranging from ~5-80 ng/mL.  To directly analyze the effects of 
insulin on the nuclear exclusion of Foxa2, we isolated primary hepatocytes 
from these mice and subjected them to controlled amounts of insulin.   
As evidenced by quantitation of nuclear and cytoplasmic extracts, an 
overnight “fast” (serum withdrawal) is sufficient to restore Foxa2 to the 
nucleus of primary hepatocytes derived from different hyperinsulinemic mouse 
models, when left untreated (Figure 3).  This demonstrates that there is no 
inherent/irreversible defect in these cells that results in nuclear exclusion of 
Foxa2. Furthermore, Foxa2 is excluded from the nucleus and localizes to the 
cytosol in a dose-dependent manner in response to insulin in all hepatocytes.  
Thus, alterations in the insulin levels alone are sufficient to induce nuclear 




Figure 3.  Insulin-dependent Foxa2 localization in primary hepatocytes.  Nuclear and cytoplasmic 
extracts were prepared from primary hepatocytes of wild-type C57Bl/6, ob/ob, db/db, and HF diet-
induced obese mice, which were incubated for 6 h in the presence of varying amounts of insulin.  
Foxa2 was detected by immunoblotting, quantified by densitometry and normalized to -Tubulin.  
Data are means ± SD, n=2. 
 
 
Notably, while insulin removal completely restored Foxa2 to the nucleus 
in hepatocytes of ob/ob, db/db and HF diet mice, higher concentrations of 
insulin were needed to re-induce nuclear exclusion.  In hepatocytes from 
wildtype C57Bl/6 mice, Foxa2 was already cytoplasmic at 1 ng/mL insulin.  
However, this concentration of insulin results in only ~20-25% nuclear 
exclusion in ob/ob, db/db and HF hepatocytes, demonstrating that their 
hepatocytes do retain a low level of insulin resistance in culture.   
 
1.2  Genetic strain variations affect metabolic parameters 
Diabetic mouse models represent an extreme metabolic phenotype.  
However, even wild-type strains have been shown to display differing 
propensities for weight gain and development of features of the metabolic 
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syndrome.  C57Bl/6 mice, for example, are more obese, glucose intolerant, 
hyperinsulinemic, and hyperletpinemic than Sv129 mice on either regular chow 
or a high-fat diet, and are more susceptible to the development of insulin 
resistance and diabetes (51, 52).  While these genetic discrepancies cannot be 
traced to single genetic alterations, it has subsequently been found that 
different strains have varying levels of circulating hormones such as insulin, and 


















         
Glucose (mg/dL) 83 ± 9 164 ± 11 90 ± 10 171 ± 21 81 ± 7 199 ± 21 100 ± 10 255 ± 31 
Insulin (ng/mL) 0.14 ± 0.04 0.31 ± 0.06 0.22 ± 0.05 0.48 ± 0.07 0.25 ± 0.04 0.63 ± 0.1 0.31 ± 0.05 1.7 ± 0.12 
Cholseterol  104 ± 10 103 ± 13 106 ± 11 104 ± 13 94 ± 13 90 ± 11 92 ± 10 80 ± 9 
Triglycerides 104 ± 12 102 ± 34 101 ± 11 100 ± 33 99 ± 14 99 ± 27 87 ± 13 84 ± 31 
Ketone bodies 2.6 ± 0.2 2.5 ± 0.2 2.4 ± 0.2 2.6 ± 0.3 2.6 ± 0.2 1.9 ± 0.2 2.5 ± 0.3 1.3 ± 0.2 
Liver triglycerides 19 ± 3 20 ± 2 20 ± 2 20 ± 2 22 ± 3 25 ± 2 24 ± 2 30 ± 2 
Glycogen n.d 3.1 ± 0.4 n.d 3.5 ± .5 n.d 3.5 ± .6 n.d 3.3 ± .5 
Table 1.  Metabolic parameters of different mouse strains.  Fasting and fed blood glucose, plasma 
insulin, cholesterol, triglycerides and ketone bodies, liver triglycerides and glycogen were measured 
from 6 male mice age 10-14 weeks.  Data are means ± SD. 
 
Initially we chose to investigate four different mouse strains:  Sv129 
(129), CD1, DBA, and C57Bl/6 (B6).  As shown in Table 1, these mice exhibit 
striking differences in their metabolic parameters, with 129 mice having the 
lowest insulin levels, and B6 mice the highest.  While B6 mice tended to have 
lower circulating cholesterol and triglyceride levels in fasting and fed states, 
these differences were not significant.  However, circulating ketone body 
concentrations were significantly decreased in fed DBA and B6 mice, inversely 
correlated to plasma insulin levels.  Additionally, circulating ketone bodies were 
significantly decreased in the fed state compared to the fasted state in DBA and 
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B6 mice, while no significant differences between fed and fasted states were 
observed in 129 or CD1 mice.  We analyzed the rate of β-oxidation in livers of 
these mice in fasted and fed states, and observed similar results.  Both in the 
fed and fasted state, DBA and B6 mice had the lowest rates of mitochondrial β-
oxidation, while 129 and CD1 animals exhibited the highest rates (Figure 4).  
Furthermore, no change in rate was observed between fed and fasting states in 
the latter two strains, while increased β-oxidation was observed in the fasted, 
compared to the fed state of the DBA and B6 mice.   
 
Figure 4.  Fasting and fed β-oxidation rates varies between strains.  Mitochondrial β-oxidation was 
measured from livers as a function of 14CO2 production from [1-14]C-palmitic acid.   n≥4. 
 
1.3   Foxa2 and Foxo1 localization in different mouse strains 
The differences in insulin levels, as well as the observed correlation with 
the downstream regulation of β-oxidation and ketone body metabolism, 
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encouraged us to analyze the nuclear localization of Foxo1 and Foxa2.  These 
two transcription factors have been shown to regulate metabolic genes and are 
inhibited by insulin signaling in the liver.  Foxa2, in particular, has been shown 
to increase fatty acid oxidation and ketone body production, while Foxo1 is 
preferentially involved in the activation of gluconeogenesis (10, 55).   
Nuclear extracts were prepared from livers of mice from all four strains 
(129, CD1, DBA, and B6), which were either ad libitum fed, fasted, or injected 
with 10 ng/mL insulin through the portal vein.  Western blotting of nuclear 
fractions revealed that both Foxo1 and Foxa2 remain nuclear in fed and fasted 
Sv129 and CD1 mice, while both are excluded from the nucleus in fed DBA 
and B6 mice (Figure 5).  
Furthermore, we could show that this is not an inherent defect in the 
signaling ability or nuclear export mechanism in the livers of these mice, since a 
bolus injection of insulin restored nuclear export of both Foxo1 and Foxa2.   
Thus, insulin is able to enact nuclear exclusion of Foxo1 and Foxa2 to a similar 
extent in livers of all four strains.  This suggests that the differential regulation 
observed in ad libitum fed states is a function of plasma insulin levels, which are 
below the necessary threshold to achieve this effect, even in a fed state, in 129 




Figure 5.  Strain variation in nuclear localization of Foxa2 and Foxo1.  Immunoblots of nuclear 
extracts from livers of fasted, fed and fasted, insulin-injected Sv129, C57Bl/6, CD1, and DBA mice. 
1.4   Decreased insulin signaling, but increased sensitivity in Sv129 and 
CD1 mice  
To determine the more general hepatic effects of different circulating 
concentrations of insulin in these strains, we perfused livers with increasing 
amounts of insulin and analyzed insulin signaling pathways by western blotting 
and RT-PCR.  Total levels of insulin receptor (IR), insulin receptor stubstrates 
1 and 2 (Irs-1, Irs-2) and Akt expression remained unchanged in all strains 
during insulin perfusion, however we observed an increase in Akt 
phosphorylation, as well as Mapk phosphorylation, in response to increasing 
insulin concentration in the perfusate (Figure 6).  Accordingly, decreased levels 
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of nuclear Foxa2 and Foxo1 were observed in all strains with increasing 
concentrations of insulin.  RT-PCR analysis revealed that the expression of 
downstream target genes of Foxa2 and Foxo1 is also inhibited by insulin 
(Figure 7). 
As a functional readout we measured β-oxidation and ketone body 
production in the livers of these mice.  Again, insulin resulted in decreased β-
oxidation and ketone body production in all strains in a dose-dependent 
manner (Figure 8).  Notably, 129 and CD1 strains were even more insulin 
sensitive, showing earlier activation of insulin signaling pathways and greater 
levels of target gene suppression at lower concentrations of insulin.  This 
suggests that the altered metabolic rates observed between these strains are 
directly correlated to plasma insulin levels, insulin signaling and Foxa2 and 




Figure 6.  Insulin perfusion shows strain variations in insulin signaling.  Livers from B6, 129, DBA and 
CD1 mice were perfused with increasing concentrations of insulin and activation of insulin signaling 
pathways was analyzed by immunoblotting whole cell or nuclear (n) lysates.  TBP, Tata-binding 




Figure 7.  Strain variation in repression of metabolic genes by insulin.  RT-PCR from livers of B6, 129, 
DBA and CD1 mice perfused with increasing concentrations of insulin.  Pepck, Phosphoenolpyruvate 
carboxykinase;  CptI, Carnitine palmitoyltransferase 1; Mcad, Medium chain acetyl-coA 
dehydrogenase; b-DH, 3-Hydroxybutyrate dehydrogenase; Acet, Acetyl-CoA Synthase; Mtp, 




Figure 8.  Strain variations in ketone body production and β-oxidation in response to insulin.  Ketone 
body production and mitochondrial β-oxidation were measured from livers as a function of 14CO2 
production and 14C- acid-soluble products, respectively, from [1-14]C-palmitic acid.  n≥4. 
 
1.5  Constitutive activation of Foxa2 increases hepatic lipid metabolism 
in livers of Fed C57Bl/6 mice 
To more directly determine what effect the amount of active/nuclear 
Foxa2 has on the observed metabolic discrepancies in these mouse strains, we 
injected ad libitum fed Sv129 and C57Bl/6 mice with constitutively active Foxa2 
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(T156A) adenovirus.  As shown in Figure 9, cellular fractionation confirmed 
that endogenous Foxa2 is nuclear in livers of 129 mice, but cytoplasmic in 
livers of B6 control mice injected with GFP adenovirus.  Adenovirally 
expressed Foxa2-T156A is constitutively nuclear in livers of both strains.   
 
Figure 9.  Localization of Foxa2 and Foxa2-T156A in livers of 129 and B6 mice.  129 and B6 were 
injected with 1E9 PFU of GFP or Foxa2-T156A adenovirus.  Six days post injection, mice were 
sacrificed, livers were fractionated, and nuclear and cytoplasmic extracts were analyzed for Foxa2 
localization by western blotting. 
 
As shown in (Figure 10), expression of constitutive active Foxa2 leads to 
a significant increase in mitochondrial β-oxidation in B6 mice, where 
endogenous Foxa2 is inactive.  Conversely, the effect of Foxa2-T156A is not 
significant in 129 animals, which already have active Foxa2 in the nucleus.   
 
 
Figure 10.  Activation of Foxa2 restores β-
oxidation in livers of Fed B6 mice.
Mitochondrial β-oxidation measured in 129
and B6 mice six days post injection with
either Ad-GFP or constitutively active (Ad-
T156A) Foxa2.  Data are means ± SD, n≥4.
** , p<0.01 by students t-test. 
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RT-PCR reveals a similar trend in expression of genes involved in β-
oxidation and ketone body synthesis.  Foxa2-T156A results in significant 
upregulation of CptI, Mcad, Vlcad, and b-DH in B6 mice, compared to GFP 
controls, while Pepck gene expression (encoding the rate-limiting enzyme for 
heptatic gluconeogenesis) is unchanged (Figure 11).  Foxa2-T156A also 
increases expression of these genes in Sv129 mice, however to a lesser extent, 
and only Cpt is significantly upregulated. 
 
Figure 11.  T156A-Foxa2 re-activates expression of B-oxidation genes in the liver.  Relative expression 
levels of genes involved in B-oxidation, ketone body synthesis and gluconeogenesis were analyzed by 
real time PCR from livers of 129 or B6 mice adenovirally expressing GFP or Foxa2-T156A (T156).  
Data are means ± SD, n≥4.  
1.6  Summary 
These studies demonstrate that genetic strain variations, in mice as in 
humans, play an important role in determining metabolic phenotypes.  Here we 
show that nuclear localization of Foxa2 (and Foxo1) correlates with 
physiological insulin levels in four different mouse strains.  Sv129 and CD1 
23 
 
mice, which have low physiological levels of insulin, retain Foxa2 in the nucleus 
even in fed states.  DBA and C57Bl/6 mice have higher insulin levels, which 
are sufficient to induce nuclear export and inactivation of Foxa2 in the fed 
state.  This data also provides a possible explanation for the lack of Foxa2 
shuttling observed by Zhang and colleagues (11).  Interestingly, constitutive 
activation of Foxa2 in livers of fed B6 mice is sufficient to restore 
mitochondrial β-oxidation to fasting levels, similar to fed Sv129 mice, and 
suggests that the differential regulation of Foxa2 plays a major role in liver lipid 
metabolism, and the metabolic phenotype. 
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CHAPTER 2:  Shuttling of Tagged Foxa2 
2.1  Functional analysis of the Foxa2 Akt phosphorylation site 
We have shown that Akt phosphorylation of Foxa2 at T165 mediates its 
nuclear exclusion and transcriptional inactivation in response to insulin; 
however the mechanisms involved in this regulation remain unclear.  It has 
been observed that the Foxa2 Akt site (RRSYTH) does not perfectly match the 
canonical Akt recognition motif (RARSYS/TH), yet it is evolutionarily 
conserved in Foxa2.  To attempt to address whether this imperfection has 
some additional significance in the regulation of Foxa2, we generated two 
variants with canonical Akt sites:  Foxa2-pAins was generated by inserting an 
additional alanine after R152, while Foxa2-pMut was generated by mutating 
Y151R and R152A.  In reporter assays both Foxa2-pAins, and Foxa2-pMut 
showed similar transactivation levels to wildtype Foxa2 under basal conditions, 
Figure 12.  Transactivation of Foxa2
Akt site variants.  HepG2 cells were
transfected with expression vectors
containing Foxa2 or variants, alone or
in combination with DN-Akt or Akt2.
p6xCdx-TkLuc was used as a reporter
gene, normalized to renilla luciferase,
and shown relative to vector only
controls.  Experiments were
performed in triplicate and are




similar increases when coexpressed with dominant negative Akt (DN-Akt), and 
all were repressed to a similar degree by coexpression of wildtype Akt (Figure 
12).  Thus, it appears that the exact sequence of this Akt site is not essential for 
the regulation of Foxa2 by Akt.  Nonetheless, we cannot rule out that alteration 
of this site might have a more subtle effect in vivo that was not observed in an in 
vitro analysis requiring cellular manipulation and overexpression.   
To further investigate the importance of this phosphorylation site we 
took advantage of the fact that Foxa1, a highly homologous member of the 
Foxa family, does not shuttle in response to insulin.  Additionally, sequence 
alignment of these two proteins revealed that Foxa1 has a T->P substitution in 
the region corresponding to the Akt phosphorylation site in Foxa2 (alignment 
of this region is shown in Figure 13.)  
 
 
We therefore asked whether introduction of the Foxa2 Akt site into 
Foxa1 would be sufficient to induce its inactivation by insulin.  This approach 
Figure 13.  Partial sequence alignment of Foxa1 and Foxa2.  The Foxa2 Akt phosphorylation site, is 
highlighted in yellow. 
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has been successfully used to identify a PGC1β-
interaction domain in Foxa2, and has also been 
used to demonstrate the importance of a 
phosphorylation motif for shuttling of Foxo3 by 
domain swapping with Foxo6 (24, 56).  Site directed 
mutagenesis was performed to clone the Foxa2 Akt site into a plasmid 
containing HA-tagged Foxa1 (Foxa1p3B), replacing the corresponding region 
in Foxa1, and its expression was confirmed by sequencing and western blot 
analysis (Figure 14).   
To test whether introduction of the phosphorylation site was sufficient 
to induce Akt-dependent inhibition of Foxa1, expression vectors for Foxa1, 
Akt2, or dominant negative Akt (DN-Akt) were coexpressed with 
pGL2hGlucP, a luciferase reporter plasmid containing the human glucagon 
Figure 14.  Expression of Foxa1 
mutants.  Whole Cell extracts 
from HepG2 cells transfected 
with pcHAFoxa1 or 
pcHAFoxa2p3B, detected with 
an α-HA antibody 
Figure 15.  Transactivation by Foxa1 and Foxa1p3B.  HepG2 cells were transfected with expression 
vectors containing Foxa1 constructs, alone or in combination with DN-Akt or Akt2.  pGL2hGlucP 
was used as a reporter gene.  Firefly luciferase activity was normalized to renilla luciferase, and 
shown relative to vector only controls.  Experiments were performed in triplicate and shown as the 
average of 3 independent experiments ± SEM. 
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promoter (shown to preferentially bind Foxa1(57)) upstream of a minimal 
promoter and the firefly luciferase gene.  Both Foxa1 variants only weakly 
transactivate the reporter, however there was no significant difference observed 
between them, with or without cotransfection of Akt or DN-Akt (Figure 15).  
If anything, transcriptional activity was stimulated by Akt, although this could 
be a general effect of increased transcription/translation caused by mimicking 
activation of a growth factor signaling pathway.   
Foxa2 transactivation, as has been previously shown (36), was enhanced 
by co-expression with dominant negative Akt, and inhibited by overexpression 
of wild-type Akt2 in parallel experiments (Figure 16).  These data suggest that 
the Foxa2 phosphorylation site alone is not sufficient to induce nuclear 
exclusion by Akt, and demonstrate that additional sequence elements might be 
necessary for the insulin-induced nuclear exclusion of Foxa2. 
 
 
Figure 16.  Foxa2 transactivation is inhibited
by Akt.  HepG2 cells were transfected with
expression vectors containing Foxa2, alone
or in combination with DN-Akt or Akt2.
p6xCdx-TkLuc was used as a reporter gene.
Firefly luciferase activity was normalized to
renilla luciferase, and shown relative to
vector only controls.  Experiments were
performed in triplicate and shown as the




2.2  Transient transfection inhibits shuttling of Foxa2 
To further elucidate the sequence elements responsible for the insulin-
induced nuclear exclusion of Foxa2 we generated N- and C-terminal Foxa2-
GFP fusion constructs (GFPN1- and GFPC1-Foxa2, respectively).  This is a 
useful approach for studying the intracellular 
localization of proteins in real time and in live cells, 
and has been previously used to visualize the 
intracellular localization of many different proteins, 
including members of the Foxo family, which also 
shuttle in response to external stimuli (56, 58-60).   
Western blot analysis confirmed the expression of a 
~90 kDa band corresponding to the predicted size 
of GFP-Foxa2 fusions (Figure 17).  However, fluorescence microscopy 
revealed that GFPC1-Foxa2 transfected into HepG2 cells was constitutively 
nuclear, despite cotransfection with Akt (Figure 18).  Insulin was also unable to 
Figure 18.  Immunofluorescent localization of GFPC1-Foxa2.  HepG2 cells were 
transfected with 20ng of pEGFP-C1 (Clontech) or GFPC1-Foxa2, with or without 
cotransfection of Akt2 (40ng), and detected by fluorescence microscopy. 
Figure 17.  Expression of
Foxa2-GFP fusion proteins.
Whole cell lysates from HepG2
cells transfected with the
indicated GFP-Foxa2
expression plasmids, separated
by SDS-PAGE and subject to
western blot analysis. 
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alter this nuclear localization, and GFPN1-Foxa2 gave similar results, with or 
without insulin or cotransfection of Akt (data not shown). 
To determine whether this effect might be due to transient transfection, 
we analyzed the localization of HA and FLAG double-tagged wildtype rat 
Foxa2 (HA-Foxa2, which has previously been shown to shuttle in response to 
insulin signaling (36)) after transfection into HepG2 cells.  Once again, even 




Figure 19.  Immunofluorescence localization of transfected Foxa2.  HepG2 cells were
transiently transfected with 20ng of HA-Foxa2, serum starved for 18 hours and treated
with or without 500nM insulin for 20minutes.  Cells were fixed and stained with anti-
HA antibody overnight at 4° and visualized with Alexa 480 Goat anti-mouse IgG using
laser scanning micrsocopy.  Nuclei were visualized by costaining with Topro3. 
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2.3  Cytoplasmic relocalization of endogenous Foxa2 by cellular 
fractionation 
Given these unexpected in vitro results and the emerging controversy 
over Foxa2 shuttling, we decided to reconfirm nuclear exclusion of Foxa2 in 
vivo, using previously established methods.   Nuclei were extracted from livers 
of fasted, random fed and ob/ob mice and assayed for the presence or absence 
of Foxa2 by western blotting.  As shown in Figure 20, Foxa2 was found in the 
nuclear fractions of livers of fasted mice, but was excluded in the livers of 
random fed and ob/ob mice.  Additionally, fasted mice injected with 150 ng of 
insulin 15 min prior to sacrifice showed nuclear exclusion of Foxa2, while PBS-
injected mice did not (Figure 21).  
 
 
Figure 20.  Nuclear exclusion of Foxa2 in livers of fed and
hyperinsulinemic mice.   Immunoblot analysis of Foxa2 in
nuclear extracts from livers of C57BL/6 and ob/ob mice,
fasted for 24 h or ad libitum fed.  Nuclear extracts were
prepared by sucrose gradient fractionation and each lane
represents livers pooled from 2 mice. 
Figure 21.  Nuclear exclusion of Foxa2 is
induced by insulin in vivo.   Immunoblot
analysis of Foxa2 in nuclear extracts from livers
of C57BL/6 mice, fasted for 24 h and injected
with PBS or 600 ng insulin via the tail vein.
Nuclear extracts were prepared by sucrose
gradient fractionation.  The upper band is non-




While these data demonstrate robust nuclear exclusion of Foxa2, thereby 
confirming previous results, the experimental protocol did not allow for 
simultaneous analysis of cytoplasmic fractions, an ideal internal control.  We 
therefore sought to develop a robust assay for determining the cellular 
localization of this factor both in vitro and in vivo.  We subsequently used a 
gentle hypotonic lysis buffer to release cytoplasmic proteins, followed by brief 
centrifugation to pellet nuclei, which were ultimately extracted by addition of 
ammonium sulfate to 400 mM.  This method of cellular fractionation yielded 
good resolution of nuclear and cytoplasmic fractions in liver tissue, as indicated 
by the predominantly nuclear localization of the TAF100 transcription factor 
(Figure 22).  Moreover, it allowed us to visualize not only the nuclear exclusion 
of Foxa2, but the corresponding cytoplasmic relocalization upon stimulation 
with insulin (and in hyperinsulinemic ob/ob mice) by cellular fractionation and 
immunoblotting.  This, in addition to the development of two new polyclonal 
Foxa2 antibodies, greatly improved our ability to accurately assay the cellular 
localization of Foxa2.   
Figure 22.  Cytoplasmic localization of
Foxa2 in livers of insulin-injected and
hyperinsulinemic mice.
Nuclear/cytoplasmic fractionation of
50 mg of frozen liver from fasted mice
injected with either PBS or insulin and
subject to immunoblotting. 
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This new protocol allowed us to revisit the impaired shuttling of 
transfected Foxa2.  Nuclear and cytoplasmic extracts confirmed shuttling of 
endogenous Foxa2 in untransfected HepG2 cells after stimulation with insulin, 
verifying that Foxa2 also shuttles in vitro (Figure 23, null).  However, after 
transfection of the cells with either PCDNA3 vector and GFP, or HA-Foxa2 
and GFP, neither transfected HA-Foxa2 nor endogenous Foxa2 shuttled in 
response to insulin (Figure 23). 
    
Figure 23.  Endogenous and HA-Foxa2 are nuclear after transfection.  HepG2 cells were transfected 
with either GFP and pcDNA3 (GFP), or GFP and HA-Foxa2 (HAFoxa2), not transfected (null) or 
mock transfected with Fugene only, serum starved for 19 h and treated with or without 500 nM insulin 
for 15 min.  Cellular fractionation was followed by SDS-PAGE and immunoblot analysis using the 
indicated antibodies. 
 
Mock transfection of the cells with Fugene transfection reagent did not 
alter the shuttling of endogenous Foxa2, demonstrating that this is not strictly 
an issue of toxicity caused by the transfection reagent.  The same nuclear 
phenotype was observed when we transfected different concentrations of 










2.4   Nuclear/Cytoplasmic shuttling of tagged Foxa2 
To avoid the issue of altered protein regulation after transfection, we 
generated stable cell lines expressing N- and C-terminal GFP-Foxa2 fusion 
plasmids in HepG2 cells.   In the process of selecting stable cell lines we found 
that GFP-Foxa2 fusions occasionally integrated in such a way as to cause 
truncation of the fusion product.  Clonal populations were selected based on 
fluorescence, and fusion constructs were detected by immunoblot analysis of 
whole cell extracts using an anti-HA antibody (Figure 25).  Therefore, the 
truncations were generally predicted to have been shortened from the C-
terminus, with the exception of GFPN1-Foxa2 clone #2, which is around 50 
kDa and appears to have retained both the N-terminal HA-tag and C-terminal 
GFP.   
Figure 24.  GFPC1-Foxa2 is nuclear after transfection.  HepG2 cells were transfected with
either 4 or 12 ug of GFPC1-Foxa2, or untransfected (null), serum starved for 19 h and treated
with or without 500 nM insulin for 15 min.  Cellular fractionation was followed by SDS-
PAGE and immunoblot analysis with anti-Foxa2 antibody. 
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Although we did not sequence the constructs to determine exactly where 
truncations occurred, we took advantage of their size differences to investigate 
Figure 25.  Stable expression of GFP-Foxa2 fusion constructs.  Clonal populations of HepG2 cells
were selected for G418 resistance and fluorescence, and screened for expression of GFP-Foxa2
fusion products in whole cell extracts by immunoblotting with anti-HA and anti-GFP antibodies 
Figure 26.  Impaired shuttling of GFP-Foxa2 in stable cell lines.  Immunoblots of nuclear and 
cytoplasmic extracts from HepG2 cells stably expressing GFPC1-Foxa2, GFPN1-Foxa2, or truncations 
thereof, with and without stimulation with 500nM insulin for 15min.  HA antibody was used to
identify stably expressed Foxa2 variants, Foxa2 antibody was used to assay endogenous Foxa2, and γ-
Tubulin was used as a loading control.
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the shuttling properties of shortened fusions alongside the full-length 
constructs.  This allowed us to simultaneously assess whether stable expression 
and/or total size reduction could enable shuttling of GFP-Foxa2.  GFPC1-
Foxa2 #17, which is around 37 kDa and presumably contains less than 10 kDa 
of Foxa2, was the smallest fusion protein generated.  While this one did show a 
general cytoplasmic shift in its distribution, the rest of the fusion constructs 
remained nuclear, and none were excluded from the nucleus after stimulation 
of the cells with insulin (Figure 26).  Endogenous Foxa2, on the other hand, 
shuttled to the cytoplasm in all GFPC1-Foxa2 stable cell lines, suggesting that 
the loss of nuclear export observed with the GFP fusion constructs is not due 
to decreased insulin sensitivity, but rather is an artifact caused by fusion to 
GFP. 
To further ensure that this was not 
an in vitro issue, we generated adenovirus 
from the GFPC1-Foxa2 construct and 
injected this into wildtype mice.  Once 
again, the GFPC1-Foxa2 construct was 
clearly nuclear in livers from both fasted 
and fed mice (Figure 27).  Taken together, 
these data demonstrate that both transfection and GFP-fusion inhibit insulin-
induced nuclear exclusion of Foxa2. 
Figure 27.  AdGFPC1-Foxa2 remains
constitutively nuclear in fasted and fed mice.
Immunoblots showing cellular fractionation
of livers from fasted or ad libitum fed




As opposed to GFP, which encodes a protein of roughly 30 kDa, HA 
and FLAG peptides are hydrophilic and immunogenic fusion tags that are 
specifically designed to facilitate purification and detection using monoclonal 
antibodies.  Due to their small size, they are less likely to interfere with protein 
function (61). We therefore established stable cell lines expressing N-terminal 
HA and FLAG double-tagged Foxa2 (HA-Foxa2) in HepG2 cells.  Indeed, 
cellular fractionation showed that stably expressed HA-Foxa2 was almost 
completely excluded from the nucleus (and relocated to the cytoplasm) by 15 
minutes after stimulation with insulin in each cell line (Figure 28).   
 
Figure 28.  Nuclear-ctyosolic shuttling of HA-Foxa2 in vitro.  Nuclear and cytoplasmic fractionation 
of HepG2 cells stably expressing HA-Foxa2 (3B4, 3B6, 3B10 denote individual clones), with and 
without stimulation with 500nM insulin for 15min.  LSD1, and GAPDH were used as nuclear and 
cytoplasmic loading control markers, respectively. 
2.5  Summary 
Here we show that Foxa2 shuttling is disrupted by transient transfection 
in HepG2 cells in vitro.  We have also tested shuttling in HEK293, and Huh7 
cells, using various transfection methods with similar results (data not shown).  
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While we were not able to elucidate the cause of this impaired shuttling, our 
data suggest that it is a consequence of the transfection procedure.  We have 
further shown that GFP fusion to Foxa2 ablates its nuclear export.  This effect 
is independent of transfection, as we achieved the same results in stable cell 
lines, and by adenoviral expression in vivo.    
Previously shuttling of Foxa2 had only been observed by its absence in 
nuclear extracts, or by immunofluorescent staining.  Here we demonstrate the 
nuclear exclusion and cytoplasmic relocalization of Foxa2 by cellular 
fractionation, both in vitro and in vivo.  Finally, we show that Foxa2 shuttling is 
not disturbed by HA/FLAG epitope tagging, thereby confirming previous data 




CHAPTER 3: Nuclear export-independent inhibition of Foxa2 
3.1  Foxa2 Contains a Nuclear Export Sequence 
To identify possible mechanisms responsible for the nuclear export of 
Foxa2 we used a candidate approach focusing on CRM1 (also called 
exportin1/Xpo1) as the most common nuclear export factor. Since CRM1 
mediated nuclear export can be potently inhibited by the pharmacological agent 
leptomycin B (LMB) (62, 63) we used this to analyze CRM1-dependent 
shuttling of Foxa2 in the 3B10 HepG2 cell line stably expressing HA-Foxa2 
(3B10, Figure 31).  Analysis of nuclear and cytoplasmic extracts showed that 
LMB prevents the export of Foxa2 from the nucleus after stimulation with 
insulin, while untreated control cells display normal export dynamics (Figure 
29). This finding demonstrates that nuclear export of Foxa2 is mediated by 
CRM1. 
 
Figure 29.  LMB inhibits nuclear export of Foxa2. Cellular fractionation of HepG2 cells stably 
expressing HA-tagged Foxa2, serum-starved overnight and stimulated with 500nM insulin, with or 




To identify possible regulatory sites in Foxa2 we performed a 
comparative analysis of the primary amino acid sequence using the generally 
accepted CRM1 consensus sequence, LX(2,3)[LIVFM]X(2,3)LX[LI] (62, 64).  
Interestingly, Foxa2 contains one leucine-rich sequence that closely resembles 
this consensus nuclear export signal (NES) as shown in Figure 30, aligned to 
the prototypical HIV-REV NES.  This region lies in the N-terminal half of 
Foxa2, about 40 amino acids upstream of the Akt phosphorylation site (T156), 
between the transactivation and DNA binding domains, and is evolutionarily 
well-conserved (Figure 30 and Figure 31).   
 
Figure 30.  Partial sequence alignment of Foxa2 from six different species, and the HIV-REV NES.  
The putative NES (red) and phosphorylated threonine (blue) are highlighted.  H, human; R, rat; M, 





Figure 31.  Schematic depiction of Foxa2 showing the putative NES in relation to other known 
domains, along with mutant constructs.  II-V, transactivation domains; NES, nuclear export signal; p, 
phosphorylation site; NLS, nuclear localization signal (N- or C-terminal of the DNA binding 
domain); DBD, DNA binding domain; PGC1β, PGC1β interaction domain; Foxa2, rat wildtype Foxa2; 
T156A, mutated at residue T156A; Emut, mutated at residues L110A and L113A; TAE, mutated at 
residues T156A, L110A, and L113A. 
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3.2  Foxa2 NES is Necessary for Nuclear Export 
To elucidate whether the putative CRM1 NES is responsible for nuclear 
export of Foxa2, and thus important for its regulation in different physiological 
states, we performed mutational analyses.  Since the C-terminal hydrophobic 
residues of the CRM1 consensus sequence have been shown to be the most 
critical for nuclear export (65), we mutated both terminal leucines (L110 and 
L113) of the putative Foxa2 NES to determine whether this sequence is 
necessary for nuclear exclusion in response to insulin.  L110A, L113A Foxa2 
(Emut, Figure 31) was stably expressed in HepG2 cells, and analyzed for its 
ability to shuttle from the nucleus in response to insulin stimulation.  
Endogenous Foxa2 was used as an internal control.  We show that while 
endogenous Foxa2 still shuttles in 
these cells in response to insulin 
stimulation, the export mutant 
remains nuclear, demonstrating that 
the NES is functional and necessary 
for export in vitro (Figure 32).   
 To test whether this sequence is 
also necessary for export in vivo and 
thus might play an important role in the 
Figure 32.  Nuclear/cytoplasmic shuttling of 
Foxa2 Emut in vitro.  Immunoblots showing 
cellular fractionation of HepG2 cells stably 
expressing Emut Foxa2, serum-starved 
overnight and stimulated with 500nM insulin. 
γ-Tubulin was used as a general loading 
control, and LSD1 and GAPDH served as 




hormonal regulation of Foxa2 activity we generated a recombinant adenovirus 
containing export mutant (Ad-Emut) Foxa2 and injected it into C57Bl/6 mice. 
As controls we treated mice with recombinant adenoviruses expressing 
wildtype (Ad-Foxa2) or phosphorylation-deficient, constitutively active Foxa2 
(Ad-T156A), which have been previously characterized (10).  All constructs 
were HA- and FLAG-tagged, and GFP adenovirus was used as an additional 
control.  As shown in Figure 33, both endogenous and exogenous Foxa2 were 
nuclear in all fasted animals.  However, while endogenous and Ad-Foxa2 were 
excluded from the nucleus in random fed animals, the export mutant (as well as 
the T156A control) remained nuclear.  Thus, the newly identified NES in 
Foxa2 is responsible for the active nuclear export of Foxa2 in hepatotcytes 




Figure 33.  Ad-Emut is deficient in nuclear export in vivo.  Immunoblots showing cellular
fractionation of livers from C57BL/6 mice infected with GFP, Foxa2, T156A, or Emut adenovirus.
Five days post-infection, mice were either fasted for 18 h (S) or ad libitum fed (F). 
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3.3  Emut Foxa2 is inhibited by insulin signaling 
The ability to study the effect of phosphorylation uncoupled from 
subcellular localization of Foxa2 led us to ask whether regulation of Foxa2 
activity by insulin is mainly controlled by nuclear export or by phosphorylation 
at T156.   To explore this latter possibility, we first sought to determine if Emut 
Foxa2 could be efficiently phosphorylated through insulin signaling.  Primary 
hepatocytes were isolated from C57Bl/6 mice, infected with the corresponding 
adenoviruses and serum starved overnight, followed by a 15 minute incubation 
with insulin.  Exogenous Foxa2 was immunoprecipitated and subjected to 
western blot analysis with an anti-Foxa2T156-specific phosphopeptide 
antibody.  Western blots show that Emut Foxa2 is phosphorylated to a similar 
extent as wildtype Foxa2, suggesting a segregation of postranslational 
modification and cellular localization.  
To further clarify this point we generated recombinant adenovirus 
expressing a double Foxa2 mutant protein (TAE, Figure 31), containing both 
the Emut and T156A mutations. The T156A and TAE mutants, both of which 
lack the phosphorylation site and thus serve as negative controls, are not 
detected by the phospho-specific antibody (Figure 34).  
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Figure 34.  Insulin results in phosphorylation of Emut Foxa2.  Primary hepatocytes isolated from 
C57BL/6 mice were infected with the indicated adenovirus, serum starved overnight and stimulated 
with 100nM insulin.  Whole cell extracts were subject to immunoprecipitation using an anti-HA 
antibody.  Immunoblots of whole cell extracts and IPs were probed with antibodies against HA and 
phospho-Foxa2 (P-Foxa2).   
 
Since the export mutant is phosphorylated in response to insulin 
signaling, we hypothesized that, despite its nuclear localization, Foxa2 could 
still be inactivated by its Akt dependent phosphorylation.  To test this 
hypothesis, we first expressed wildtype Foxa2, T156A, or Emut plasmids 
together with a reporter plasmid containing six Foxa binding sites of the 
murine Cdx-2 gene upstream of firefly luciferase (6xCdx), with or without Akt2, 
in HepG2 cells.  Reporter assays showed that while the export mutant retained 
transcriptional activity under basal conditions, cotransfection with Akt ablated 
this activity to a similar extent as wildtype (Figure 35).  As a control, 
Foxa2T156A remained fully active with or without Akt coexpression.  These 
data clearly demonstrate that on a functional level Foxa2 transcriptional activity 
is primarily regulated by posttranslational modification rather than by nuclear 




Figure 35.  Akt inhibits transactiation by Emut Foxa2.  HepG2 cells were transfected with expression 
vectors containing Foxa2 constructs, alone or in combination with Akt2.  p6xCdx-TkLuc was used as 
a reporter gene.  Luciferase activity was normalized to renilla luciferase, and shown relative to vector 
only controls.  All experiments were performed in triplicate and values shown represent the mean of 
three independent experiments ± SEM.  *, p< .05; **, p<.01 by unpaired t-test. 
 
To test whether these functional changes translate to the binding of 
Foxa2 to its target promoter regions, we performed chromatin 
immunoprecipitations from C57Bl/6-derived primary hepatocytes infected 
with Ad-GFP, Ad-Foxa2, Ad-T156A, Ad-Emut and Ad-TAEmut.  In a serum-
starved state, all Foxa2 constructs were able to bind to known Foxa2 
interaction sites in CPT1, HMGCS, and L-PK genes.  However, after insulin 
stimulation, the wildtype and export mutant constructs were no longer found 
to bind the target sites, while binding of the T156A and TAE mutant Foxa2 
proteins was unaffected by insulin (Figure 36).  These data confirm the results 
obtained from the transactivation assays and show that phosphorylation 
determines binding of Foxa2 to its responsive promoter elements and that 





Figure 36.  Insulin signaling disrupts promoter binding of Emut Foxa2.  Chromatin 
immunoprecipitations from serum-starved or insulin-stimulated primary hepatocytes that were 
infected with the indicated adenoviruses. Chromatin was immunoprecipitated with HA or IgG 
(control) antibodies.  Binding of Foxa2 and mutants to promoter sites in target genes was assayed by 
PCR.  CPT1, carnitine palmitoyltransferase 1;  HMGCS, HMG CoA synthase; L-PK, liver pyruvate 
kinase. 
 
3.4  Emut is constitutively nuclear but inactive in hyperinsulinemic 
ob/ob mice 
The effect of constitutive activation of Foxa2 is most striking in 
hyperinsulinemic mouse models that show constitutive inactivation of 
endogenous Foxa2 (10).  Thus, to assess the importance of nuclear export on 
the physiological activity of Foxa2 in the context of metabolic disorders, and to 
elucidate whether the biological activities of Foxa2 mutants show the same 
regulation in vivo, we expressed Emut Foxa2 in the livers of ob/ob mice using 
recombinant adenoviruses.  Transcriptional activity, and resulting metabolic 
and physiological consequences, were compared to age and sex-matched ob/ob 
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mice injected with either wildtype, T156A, or TAE Foxa2 adenoviruses.  We 
previously demonstrated that endogenous and Ad-Foxa2 are constitutively 
cytoplasmic and inactive in hyperinsulinemic mouse models of type 2 diabetes, 
while Ad-T156A remains in the nucleus and is able to restore Foxa2 activity 
(10).  Nuclear and cytoplasmic extracts from the livers of these mice confirmed 
that endogenous and Ad-Foxa2 are constitutively cytoplasmic, while the Ad-
T156A, Ad-Emut and Ad-TAE Foxa2 constructs remain in the nucleus (Figure 
37).  Immuno-fluorescence microscopy was also used to confirm these results 
(Figure 38).   
 
Figure 37.  Emut is constitutively nuclear in ob/ob mice.  Ob/ob mice were injected with the 
indicated adenovirus and livers were analyzed 10 days post-injection by cellular fractionation and 
immunoblotting.  γ-Tubulin was used as a general loading control, and LSD1 (Lysine-specific 
demythlase 1) and GAPDH served as nuclear and cytoplasmic extraction controls, respectively. 
 
To analyze the activity of the export mutant in these mice, which is the 
most important functional readout, we measured target gene activation by real-
time PCR and assayed various metabolic parameters over 10 days.  As 
expected, mRNA levels of Foxa2 target genes involved in mitochondrial fatty 
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acid oxidation and ketone body formation (MCAD, VLCAD, CPT1α, and 
HMGCS) were upregulated in livers of the T156A-injected mice, while no 
significant change was observed in mice injected with wildtype Foxa2.  
Consistent with our previous findings, Emut Foxa2 was unable to activate 
transcription of target genes in these hyperinsulinemic mice, while the double 
mutant TAE Foxa2 restored constitutive activation (Figure 39).  As a control, 
we checked Foxa2 mRNA levels, which were upregulated roughly 2-fold in all 
mice, relative to Ad-GFP controls (Figure 40).  
 
 
Figure 38.  Immunofluorescence localization of Foxa2 variants in ob/ob liver.  Ob/ob mice were 
injected with the indicated adenovirus and livers were frozen in OCT 10 days post-injection.  
Cryosections stained with anti-HA and Donkey anti-rabbit IgG Alexa Fluor 488 (Green) and Dapi 






Figure 40.  Foxa2 mRNA levels in
adenovirus-injected ob/ob mice.  Primers
were designed to recognize both rat and
mouse isoforms.  Values shown represent
the mean ± SEM, n≥3. 
 
Figure 39.   Mean mRNA levels of Foxa2 
target genes in livers of ob/ob mice 
injected with the indicated adenovirus, 
n≥3.  MCAD, medium chain acyl-CoA 
dehydrogenase; VLCAD, very long chain 
acyl-CoA dehydrogenase; CPT1α, 
carnitine palmitoyltransferase 1α; 
HMGCS, HMG CoA synthase.  Colors as 
in Figure 40. 
Figure 41.  Emut does not activate
mitochondrial β-oxidation in ob/ob livers.
The formation of 14CO2 from 14C-palmitic acid
was measured from liver mitochondrial
extracts from ob/ob mice 10 days after
injection with the indicated adenovirus.
Values shown represent the mean ± SEM.  *,
p< 0.05; **, p<0.01; ***, p< 0.001 by unpaired
t-test compared to Ad-GFP; n≥4.   
Figure 42.  Emut does not activate liver ketone
body production in ob/ob mice.  The
formation of 14C-acid-soluble products from
14C-palmitic acid was measured from liver
mitochondrial extracts from ob/ob mice 10
days after injection with the indicated
adenovirus. Values shown represent the mean
± SEM.  *, p< 0.05; **, p<0.01; ***, p< 0.001
by unpaired t-test compared to Ad-GFP; n=4.  
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As a physiological readout, we measured hepatic mitochondrial fatty acid 
β-oxidation and ketone body production in the livers of hyperinsulinemic ob/ob 
mice that were infected with either Ad-GFP, Ad-Foxa2, Ad-T156A, Ad-Emut, 
or Ad-TAE.  Consistent with the gene expression data, fatty acid oxidation and 
ketone body production remained unchanged in the Ad-Foxa2 and Ad-Emut 
injected mice, indicating that both are functionally inactive in hyperinsulinemic 
conditions.  On the contrary, phosphorylation-deficient Ad-T156A and Ad-
TAE groups were immune to inactivation by insulin and showed significant 
increases in fatty acid metabolism (Figure 41, Figure 42).  
 
Figure 43.  Liver and Plasma lipids in adenovirus-injected ob/ob mice.   (A) Lipids were extracted 
from 50 mg of liver tissue by the Folch method, weighed and recorded as a percentage of the original 
tissue weight.   (B) Triglycerides were measured from plasma samples taken after a moderate 6 hour 
fast over the course of the experiment. Values shown represent the mean ± SEM.  *, p< 0.05; **, 
p<0.01; ***, p< 0.001 by unpaired t-test compared to Ad-GFP; n≥4. 
 
As an additional readout of fatty acid metabolism we assayed liver lipids 
and plasma triglycerides.  Hepatic lipid content (shown as percent wet weight) 
revealed a similar trend Figure 43A), with decreases observed only in Ad-
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T156A and Ad-TAE groups.  Plasma triglycerides showed an inverse trend 
(Figure 43B). 
Blood glucose and plasma insulin levels were also measured in these 
mice, and both decreased significantly over 10 days in the T156A and TAE 
groups mice, whereas no decrease was seen in Ad-Foxa2 or Ad-Emut groups 
(Figure 44, Figure 45).  In contrast to previous assumptions, these data 
demonstrate that nuclear exclusion is not necessary for insulin-induced 
transcriptional inactivation of Foxa2.  
 
  
Figure 44.  Emut is unable to normalize 
blood glucose in ob/ob mice.  Blood 
glucose was measured from plasma samples 
taken after a moderate 6 hour fast over the 
course of the experiment.  Values shown 
represent the mean ± SEM.  *, p< 0.05; **, 
p<0.01; ***, p< 0.001 by unpaired t-test 
compared to Ad-GFP, n=5. 
 




Figure 45.  Emut is unable to decrease 
plasma insulin levels in ob/ob mice.  
Insulin was measured from plasma 
samples taken after a moderate 6 hour fast 
over the course of the experiment. Values 
shown represent the mean ± SEM.  *, p< 
0.05; **, p<0.01; ***, p< 0.001 by unpaired 




3.5  Summary 
Herein, we demonstrate that Foxa2 contains a functional CRM1-
dependent (LMB-sensitive) nuclear export site, which is necessary for its 
nuclear exclusion in response to insulin stimulation.  Our data clearly 
demonstrate that ablation of the nuclear export site, both in vitro and in vivo, 
results in constitutively nuclear Foxa2 that is still rendered transcriptionally 
inactive upon insulin stimulation.  In addition, we have shown that 
phosphorylation at T156 is necessary for both nuclear export and 
transcriptional inactivation, since export mutants that are constitutively located 
in the nucleus are still phosphorylated by insulin signaling, and additional 
T156A mutation restores constitutive Foxa2 activity.  Thus, we show here for 
the first time that intracellular relocation is a secondary effect and that Akt-
dependent phosphorylation is a more direct determinant of Foxa2 activity and 
its physiological functions in maintaining hepatic lipid metabolism.   
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CHAPTER 4:  Pulmonary Regulation of Foxa2 by insulin 
4.1  Foxa2 expression in the lung 
As previously mentioned, Foxa2 is expressed early in development in the 
node, notochord and floor plate, while in adult animals it is expressed in 
endodermally derived tissues such as the liver, pancreas, lung and gut (19, 31, 
66, 67).  While the lung is not generally considered an insulin-sensitive organ, it 
does play a role in metabolism.  In addition to its respiratory functions, the lung 
has been demonstrated to act as a filter for certain metabolites, such as 
serotonin, and is the main source of angiotensin converting enzyme (ACE) 
(68).  Perhaps the most well appreciated metabolic function of the lung, 
however, is the production and secretion of surfactant. 
Pulmonary surfactant is an amphipathic lipoprotein complex composed 
of ~90% lipid and 10% protein (69).  Its major function is to maintain low 
levels of surface tension at the air-liquid interface in lung alveoli, and thus allow 
for more efficient gas exchange, in addition to preventing lung collapse.  For 
this reason, surfactant production is most critical for the transition to air 
breathing at birth, although it has also been linked to breathing disorders later 
in life.  Both in mice and humans, mutations or deletions in the genes coding 
for surfactant protein B and C (SP-B and -C, two of the four major surfactant 
proteins), are associated with respiratory failure and interstitial lung diseases, 
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which can be lethal without lung transplantation (70, 71).  More recently, 
additional proteins involved in surfactant production have been linked to 
respiratory diseases including proteins involved in lipid transport such as 
ABCA3 (ATP-binding cassette A3, a lipid transporter), as well as transcription 
factors regulating the expression of important surfanctant genes such as TTF-1 
(thyroid transcription factor 1) and Foxa2 (72, 73). 
In mice, Foxa2 is expressed in a subset of respiratory epithelial cells in 
the lung throughout development.  In adult animals its pulmonary expression is 
restricted to epithelial cells of the bronchi, bronchioles, alveolar type II cells, 
and at lower levels in the trachea.  Notably, its expression overlaps both 
temporally and spatially with the expression of key surfactant genes including 
SP-B, SP-C, CCSP and TTF-1, which have been shown to be Foxa2 targets 
(74-78).  Furthermore, Wan and colleagues demonstrated that conditional 
deletion of Foxa2 in the lung impaired lung maturation and surfactant 
production, and resulted in respiratory failure and death, further emphasizing 
the crucial role of Foxa2 in lung development and surfactant production (79).    
Despite the fact that the lung is not generally considered a metabolic 
organ, demonstration of such an important role for Foxa2 activation in the 
lung caused us to speculate as to whether insulin might also inhibit the 
activation of Foxa2 in the lung, and whether this might interfere with 
pulmonary function in hyperinsulinemic conditions.  Indeed, Type 2 diabetes 
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has been suggested to be associated with certain chronic respiratory diseases 
such as asthma and COPD (80-82).  While most of the genetic abnormalities 
discussed so far result in respiratory failure and lethality, chronic lung diseases 
are more common and less well understood (83).  Additionally, there is known 
to be an increased risk of respiratory distress syndrome in newborns of diabetic 
mothers (84, 85).  These mothers are generally hyperinsulinemic, but insulin 
resistant and therefore hyperglycemic.  While insulin does not cross the 
placenta, glucose does, and an excess of blood glucose stimulates the fetal 
pancreas to produce more insulin, thus rendering the fetus hyperinsulinemic. 
Taken toghether, these findings have led us to hypothesize that increased 
insulin levels may lead to nuclear exclusion and inactivation of Foxa2 in the 
lung, thus inhibiting transcription of important surfactant genes and providing 
a link between hyperinsulinemia and respiratory problems in type 2 diabetes.   
4.2  Insulin induces nuclear exclusion of Foxa2 in the lung 
To address whether insulin induces nuclear exclusion of Foxa2 in the 
lung, fasted C57Bl/6 mice were given injections of either PBS or PBS 
containing 600ng insulin.  Ob/ob (leptin-deficient) mice were used as a model of 
hyperinsulinemia and were given no injections.  20 minutes post-injection the 
mice were sacrificed and nuclear extracts were made from whole lungs 
following a protocol previously established for the liver (10).  Livers were 
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analyzed as a positive control and, as expected, livers derived from C57Bl/6 
mice injected with insulin, as well as hyperinsulinemic ob/ob mice, showed 
nuclear exclusion of Foxa2 (Figure 21).  Similarly, the lung showed clear 
nuclear exclusion of Foxa2 in response to insulin and in ob/ob mice, even with 
25% more protein loaded in insulin and ob/ob lanes (Figure 46).   
 
Though the predicted molecular weight of Foxa2 is 50 kDa, it generally 
runs around 55 kDa by SDS-PAGE.  This is approximately the same mass as 
mouse IgG heavy chain, and the two polypeptides may comigrate in a gel. To 
ensure that the band we observed in the PBS lanes was not due to 
contaminating IgG (since  a mouse monoclonal antibody was used to detect to 
Foxa2) we probed a control blot using only anti-mouse secondary antibody.  
After an hour long exposure (compared to a 4 minute exposure in Figure 46) 
we observed minimal IgG contamination, and the intensity of the 
Figure 46.  Nuclear exclusion of Foxa2 in
lungs of insulin-treated and hyperinsulinemic
mice.  Western blots of nuclear extracts
prepared from lungs and livers of fasted
C57B6 and ob/ob mice injected with
either PBS or 600 ng of insulin.  
Figure 47.  No effect of IgG 
contamination on shuttling of Foxa2. 
Blots from Figure 46 were preincubated 
with anti-mouse secondary antibody to 
control for background bands. 
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contaminating heavy chain species was higher in the ob/ob extracts than the 
PBS samples (Figure 47).  Thus, detection of Foxa2 in these samples was not 
compromised by IgG contamination. 
To determine whether this effect was relevant at physiological levels of 
insulin, we repeated the experiment in C57Bl/6 mice that were either fasted for 
24 hours or allowed to eat normally, and again included ob/ob  mice as a 
control.  Nuclear extracts of lungs from these mice showed that postprandial 
insulin levels alone were enough to induce the nuclear exclusion of Foxa2 in 
fed mice (Figure 48).  Ob/ob  mice also showed clear nuclear exclusion of 
Foxa2.  Ponceau staining or antibody against the generic TAF100 transcription 
factor were used as loading controls.   
 
After development of the cellular fractionation protocol discussed in 
chapter 2, we repeated these experiments in triplicate in fasted, fed, insulin-
injected C57Bl/6, and ob/ob mice.  As expected, Foxa2 was once again found in 
the nucleus of lungs of fasted mice, but was excluded from the nuclear 
fractions in fed, insulin-injected and ob/ob mice (Figure 49).  Accordingly, we 
Figure 48.  Nuclear exclusion of Foxa2 in
lungs at physiological insulin levels.
Immunoblot analysis of Foxa2 in nuclear
extracts from livers of C57BL/6 and ob/ob
mice, fasted for 24 h or ad libitum fed.
Nuclear extracts were prepared by sucrose
gradient fractionation and each lane
represents livers pooled from 2 mice. 
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were able to see Foxa2 in the cytoplasmic fractions only in lungs from fed, 
insulin-injected and ob/ob mice.  
 
Figure 49.  Foxa2 relocates to the cytoplasm in lungs of fed and hyperinsulinemic mice.  Immunoblots 
of nuclear and cytoplasmic fractions from lungs of fasted, fed or insulin-injected C57Bl/6 mice, and 
fasted ob/ob mice. 
 
4.3  Surfactant gene expression in adult lung 
To determine whether the inhibition of Foxa2 in fed mice has an effect 
on surfactant gene expression we prepared RNA from lungs of fasted or ad 
libitum fed mice, and analyzed expression levels of candidate Foxa2 target genes 
by realtime PCR.  While we did observe a slight decrease in SP-A , SP-B and 
Aqp3 (aquaporin 3, a water channel protein whose transcription is activated by 
Foxa2 in reporter assays (86)), only SP-A was significantly downregulated 
(Figure 50).   
 
Figure 50.  Surfactant gene expression in lungs of fasted and fed mice.  RNA was prepared from lungs 
of C57Bl/6 mice that were fasted overnight or ad libitum fed.  RNA was reverse transcribed and 
relative gene expression was measured by quantitative realtime PCR, normalized to either GAPDH 
(left panel) or 36B4 (right panel). Values represent the mean ± SEM;  **, p<.01 by two-tailed students 
t-test relative to fasted controls, n≥3. 
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SP-A has been previously associated with Foxa2 due to its decreased 
expression in Foxa2∆/∆ lungs, and there is evidence that insulin leads to 
inhibition of SP-A in a PI3-K-dependent manner (79, 87), suggesting that it 
could potentially be a direct target.  However, this is debatable since reporter 
assays failed to show that Foxa2 can directly activate its transcription (79).   
Since the expected downregulation of SP-B and CCSP in fed mice was 
not observed by realtime PCR we took a more unbiased approach to identify 
potential Foxa2 target genes that are regulated by nutritional status.  mRNA 
was prepared from total lung RNA of fasted and fed C57Bl/6 mice, pooled, 
and compared by Affymetrix microarray hybridization.  Table 2 shows the 
most downregulated and upregulated genes in the fed compared to the fasted 
state.  Since Foxa2 generally acts as a transcriptional activator we consider the 
downregulated genes most likely to be direct targets of Foxa2.   
Once again we saw no significant changes in surfactant genes, and no 
obvious target genes linking nutritional status to pulmonary function.  It should 
be noted, however, that this experiment only compared lungs of adult, healthy, 
wildtype mice in fed and fasted states, and not more extreme hyperinsulinemic 






Gene Fold downregulation 
chloride channel calcium activated 3 46.3 
chitinase 3-like 4 23.6 
eosinophil-associated, ribonuclease A family, member 11 6.9 
resistin like alpha 6.6 
cDNA sequence BC055107 4.7 
serum amyloid A 3 4.4 
solute carrier family 26, member 4 4.3 
chloride channel calcium activated 1 ; chloride channel calcium activated 2 4.2 
cDNA sequence BC055107 3.9 
pyruvate dehydrogenase kinase, isoenzyme 4 3.9 
anterior gradient 2 (Xenopus laevis) 3.5 
angiopoietin-like 4 3.5 
PREDICTED: zinc finger and BTB domain containing 16 mRNA 3.4 
RIKEN cDNA 2210019G11 gene 3.4 
Hexaribonucleotide binding protein 3 (Hrnbp3) 3.4 
lysyl oxidase 3.3 
Transcribed locus 3.3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
l l i l f lik 2
3.3 
DNA-damage-inducible transcript 4 3.2 
Gene Fold upregulation 
cathelicidin antimicrobial peptide 8.172 
neutrophilic granule protein 3.838 
major urinary protein 1 ; major urinary protein 2 3.704 
lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 2.866 
mannosidase 2, alpha B2 2.701 
cytochrome P450, family 1, subfamily a, polypeptide 1 2.548 
WNT1 inducible signaling pathway protein 1 2.479 
Lecithin-retinol acyltransferase (Lrat), mRNA 2.455 
chemokine (C-X-C motif) ligand 7 2.417 
regulator of G-protein signaling 18 2.319 
transmembrane protein 46 2.255 
PREDICTED: Mus musculus RIKEN cDNA 9630020C08 gene  2.238 
RIKEN cDNA 8430417A20 gene 2.221 
DNA segment, human D4S114 2.217 
checkpoint kinase 1 homolog (S. pombe) 2.201 
limb-bud and heart 2.187 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
b 10
2.174 
tumor necrosis factor (ligand) superfamily, member 10 2.166 
Insulin-like growth factor 1, mRNA (cDNA clone MGC:18617  2.165 
Table 2.  Highest down and upregulated genes in fed lung.  Biotin-labelled cRNA samples from 5 
fasted and 5 fed mice were pooled and hybridized to an Affymetrix GeneChip Mouse Genome 2.0 




4.4  Nuclear exclusion of Foxa2 in Fetal lungs 
Since previous studies have demonstrated a critical role for Foxa2 in 
lung development and the transition to air breathing, we first investigated 
whether insulin also regulates the nuclear localization of Foxa2 in the fetus.  
Timed pregnancies were set up in wildtype C57Bl/6 mice and allowed to 
progress to embryonic day 19 (E19), at which point lung development is nearly 
complete (88).  Pregnant females were either fasted, or allowed to feed freely 
for 16 hours prior to sacrifice, and cellular localization of Foxa2 was assessed in 
maternal and fetal liver and lung tissue.  In accordance with previous data, 
Foxa2 is nuclear in maternal tissue from fasted mice, as well as in the lung and 
liver of fetuses from fasted mothers (Figure 51).  This is in startk contrast to ad 
libitum fed pregnant females, where Foxa2 is excluded from the nucleus in 
maternal and fetal lung and liver (Figure 52).  Here we demonstrate, for the 
first time, that Foxa2 shuttling also occurs in the fetus, and that its cellular 
localization is linked to the nutritional state of the mother. 
 
Figure 51.  Foxa2 is nuclear in liver and lung of fasted fetuses.  Nuclear and Cytoplasmic fractions 
from wildtype fasted maternal (M2) or E19 fetal (E1, E2) liver (Lv) and lung (Lu) were immunoblotted 





Figure 52.  Foxa2 is cytoplasmic in fetal liver and lung of fed mice.  Nuclear and Cytoplasmic 
fractions from wildtype ad libitum fed maternal (M) or E19 fetal (E1,4,6) liver and lung were 
immunoblotted for Foxa2. 
 
Since insulin does not cross the placenta, we could not directly test the 
effect of insulin on the localization of Foxa2 in fetal tissues by injection.  
Instead, we took advantage of two mouse models of diabetes that are 
hyperglycemic and thus induce hyperinsulinemia in the fetus.   
SREBP-1cAp2 (SREBP) transgenic mice, express nuclear Sterol 
regulatory element-binding protein (SREBP) 1c only in adipose tissue, but 
subsequently have a pronounced type 2 diabetic phenotype with marked 
hyperinsulinemia, insulin resistance and hyperglycemia (89).  Previous data 
from the lab has shown that Foxa2 is constitutively cytoplasmic and inactivate 
in livers of these mice (10).  We now show that Foxa2 is also constitutively 
cytoplasmic in lungs of these mice.  Additionally, maternal hyperglycemia in 
these animals is able to signal a constant “fed” state even in these fasted mice, 
and thus triggers insulin secretion, as evidenced by nuclear exclusion of Foxa2 




Figure 53.  Nuclear exclusion of Foxa2 in fetal lungs of SREBP mice.  Immunoblots of nuclear and 
cytoplasmic extracts from lungs of fasted SREBP mice.  M, maternal lung; E1-4, E19 fetal lung; C, 
fasted lung whole cell lysate as a control; TBP, TATA binding protein.   
 
The second mouse model we used to demonstrate the effect of aberrant 
insulin signaling on Foxa2 localization in fetal tissue is streptozotocin-induced 
diabetic mice, a model for Type I diabetes.  Streptozotocin (stz) targets and kills 
pancreatic beta cells, inducing hypoinsulinemia and, consequently, 
hyperglycemia.  Thus, these mice provide an elegant approach to studying the 
effects of maternal hyperglycemia on Foxa2 localization in wildtype fetuses.  
Fasted stz-treated mothers, in accordance with their hypoinsulinemic state, 
show Foxa2 localization in the nucleus in liver and lung (Figure 54).   
 
Figure 54.  Differential Foxa2 localization in maternal and fetal livers and lungs of Stz mice.  Pregnant 
C57Bl/6l mice were given injections of 3x75 mg/kg stz on E14-16.  Mice were fasted on E18, sacced 
on E19 and nuclear and Cytoplasmic fractions maternal (M) or E19 fetal (E1, E5) liver (Lv) and lung 
(Lu) were subject to immunoblot analysis. 
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Conversely, fetuses of these hyperglycemic mothers retain beta cell 
function and secrete insulin, which results in cytoplasmic relocalization of 
Foxa2 only in fetal tissues (Figure 54). 
To study the effect of hyperinsulinemia on gene regulation in fetal lungs 
we compared mRNA expression profiles from wildtype, fasted fetuses and stz-
treated fetuses.  Agilent microarray analysis revealed 37 genes which were 
found to be significantly downregulated and 103 genes significantly upregulated 
more than 2 fold in stz-lungs compared to fasted wildtype controls (Table 3).   
While we have not yet verified any of these genes in the lung, 
preliminary cDNA analysis of fetal livers from stz and wildtype fasted fetuses 
by RTPCR shows a significant decrease in known Foxaa2 target genes 
including MCAD, VLCAD and CPT1 (Figure 55).  This analysis was 
preliminary due to the limited n number, however it suggests that the model is 
sound.  It is also reassuring to note that several of the top downregulated genes 
in the agilent list have already been linked to Foxa2 in the literature. Reg3g, has 
been shown to be a Foxa2 target gene in vitro, and is the highest downregulated 
in our list (90).  Scgb3a1, the second most downregulated gene in stz-lungs is a 
homolog of CCSP, a secrotoglobulin also regulated by Foxa2 (91).  
Additionally, muc5b (mucin 5b) is a related to muc2, the main component of 




Gene Fold downregulation Gene Fold downregulation
Reg3g 78.98 A_52_P444116 3.77 
Scgb3a1 31.79 Chst5 3.55 
Muc5b 31.34 Krt5 3.31 
Agr2 22.71 Klk10 3.26 
Mfi2 16.90 Vip 3.23 
1110017I16Rik 16.67 A_52_P686218 3.02 
Matn3 14.50 A_52_P257026 2.95 
Col9a1 11.89 B230303O12Rik 2.92 
C1qtnf3 10.69 2310068J10Rik 2.91 
Col9a3 9.74 AK163997 2.87 
Lect1 8.63 Gzmb 2.85 
3110079O15Rik 8.34 D130076A03Rik 2.69 
Agc1 7.96 Mfsd2 2.64 
Chac1 7.22 Abcg5 2.51 
Adh7 5.65 Nr1i3 2.41 
Cart 5.22 AK154840 2.37 
A930038C07Rik 4.71 E430002D04Rik 2.03 
BC006965 4.36 Nptxr 2.01 
9030611K07Rik 4.05 
Gene Fold upregulation Gene Fold upregulation 
Pln 169.7 Akr1b7 4.8 
Prap1 71.3 Serpina1e 4.8 
Ckmt2 65.3 Agxt 4.8 
Nppa 25.5 Cyp3a41 4.7 
Ftcd 21.5 Kng1 4.7 
Dhrs7c 15.5 F13b 4.6 
C78409 14.8 Cps1 4.5 
Xist 14.4 Fabp1 4.4 
Apoa5 10.1 Abcb11 4.3 
Nefh 8.1 Pck1 4.1 
Pah 7.6 Slc10a1 4.1 
9630020C08Rik 5.9 Apoa1 4.0 
Cyp3a16 5.8 Sult1d1 4.0 
Slco1b2 5.7 Bhmt2 4.0 
Fthl17 5.7 Dmgdh 4.0 
Ankrd1 5.4 Hsd17b13 3.9 
Hfe2 5.4 Clec4f 3.9 
Angptl3 5.1 Serpina1b 3.7 
Bhmt 5.0 Spp2 3.6 
Table 3.  Genes  altered in fetal lungs of stz-mothers.  Highest up and downregulated genes in stz 
compared to fasted fetal lungs were identified using 4x44 Agilent whole mouse genome microarray 




Figure 55.  Foxa2 β-oxidation genes are inhibited in fetal livers of stz mothers.  Realtime PCR analysis 
of Foxa2 target genes in cDNA made from livers of fetuses from C57Bl/6 fasted or stz-induced 
diabetic mothers.  Values are means, normalized to GAPDH ± SEM shown relative to fasted fetal liver 
samples, which were sset to 1.  *, p≤.05; **, p ≤ 0.01.  MCAD, medium chain acyl-CoA 
dehydrogenase; VLCAD, very long chain acyl-CoA dehydrogenase; CPT1, carnitine 
palmitoyltransferase 1α.  n≥2. 
4.5  Summary 
Though the lung is not considered a major metabolic organ, we have 
found that Foxa2 localization is regulated by insulin in the lung as it is in the 
liver.  In lungs of adult mice Foxa2 is excluded from the nucleus following 
insulin injection, as well as by physiological levels of insulin experienced in the 
fed state.  Furthermore it is constitutively cytoplasmic in lungs of 
hyperinsulinemic ob/ob mice.  The increased incidence of lung disorders in 
babies of diabetic mothers, which are similar to that observed in Foxa2 lung 
conditional knockout mice, led us to search for a correlation between 
hyperinsulinemia, Foxa2 inactivation, and the production of surfactant 
proteins.  In lungs of adult mice, RTPCR and microarray analysis failed to 
provide clear evidence that Foxa2 inactivation in the fed state links nutritional 
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status to pulmonary function.  However, we did observe a slight but significant 
downregulation in SP-A gene expression by RTPCR.    
While microarray analysis of gene expression in fetal lungs from stz-
induced diabetic mothers was also unable to directly correlate Foxa2 regulation 
to surfactant production, we do clearly observe insulin-dependent inactivation 
of Foxa2 both in fetal liver and lung.  In normal mice and in mouse models of 
diabetes, we find that Foxa2 in the embryonic lung (and liver) is excluded from 
the nucleus in conditions of high blood glucose.  This sensitivity of Foxa2 to 
maternal glycemic state leaves open the possibility that there is a link between 
diabetic mothers and fetal lung development and function. 
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CHAPTER 5:  Shuttling of Foxa2 in the Hypothalamus 
5.1  Hypothalamic expression of Foxa2  
In addition to aforementioned regions, Foxa2 is also expressed in the 
brain, including certain regions of the hypothalamus (19).  Using Xgal knock-in 
mice (Foxa2+/lacZ) in which one allele of Foxa2 is replaced by the LacZ gene, we 
have further mapped the expression of Foxa2 in the central nervous system.  
X-gal staining was observed in the lateral hypothalamic area, paraventricular 
hypothalamic area, zona incerta, and substantia nigra (Silva J, unpublished 
data).  However, the function of Foxa2 in these cells is not well understood.  
Given the newly emerging view of Foxa2 as an important sensor and regulator 
of metabolic genes, we found its expression in the lateral hypothalamus 
(considered to be the feeding center of the brain) to be of particular interest 
(93).   
While the hypothalamic role of Foxa2 has not yet been appreciated, the 
anorectic effects of insulin and its subsequent activation of the 
phospatidylinositol 3 kinase (PI3K)/IRS/Akt signaling pathway in the 
hypothalamus are well documented (94-96).  In the arcuate nucleus, these 
effects have been shown to be mediated in part by suppression of orexigenic 
neuropeptides such as neuoropeptide Y (Npy) and Agouti-related protein 
(Agrp), while activating the expression of anorexigenic Pomc 
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(proopiomelanocortin) at the same time (97).  Inactivation of Foxo1 by insulin 
and leptin has been shown to play a key role in these regulatory events (98). 
Neurons in the lateral hypothalamus also respond to feeding and fasting, 
and control food intake as well as spontaneous physical activity due in large 
part to the effects of orexin and MCH (99, 100).  However, the mechanism and 
metabolic stimuli controlling their regulation in response to feeding and fasting 
is unknown.  Dual immunofluorescence labeling with Foxa2 and MCH or 
orexin reveals that all MCH and orexin positive neurons also express Foxa2 
(Silva J, unpublished data).  Thus we hypothesized that insulin-induced nuclear 
exclusion of Foxa2 could mediate feeding-induced inhibition of MCH and 
orexin, and thus appetite and food seeking behavior.  
5.2  Insulin induces nuclear exclusion and inactivation of Foxa2 in the 
hypothalamus 
To begin to address the role of Foxa2 in the hypothalamus, we first 
sought to determine whether it is inactivated by insulin signaling in this portion 
of the brain.  Hypothalami were dissected from fasted or ad libitum fed wild 
type mice, subjected to cellular fractionation and assayed for nuclear exclusion.  
As shown in Figure 56, Foxa2 is nuclear in hypothalami from fasted mice, but 
cytoplasmic in fed mice.   
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To demonstrate that this regulation is 
due specifically to increased postprandial 
insulin levels and not blood glucose 
concentrations, we isolated hypothalami 
from fasted wildtype mice and incubated 
them ex vivo in basal media with low glucose, 
high glucose, or low glucose plus insulin.  
Neither low nor high glucose concentrations 
are sufficient to induce nuclear export of Foxa2, however Foxa2 did shuttle 
when insulin was added to the low glucose media (Figure 57) 
 
Figure 57.  Hypothalamic nuclear exclusion of Foxa2 is insulin and not glucose-dependent.  
Immunoblot analysis of nuclear and cytoplasmic extracts prepared from hypothalami incubated ex 
vivo in DMEM with either low (5 mM) or high (16 mM) glucose, in the absence or presence of 10 
ng/mL of human recombinant insulin. 
 
In order to study the effects of constitutive inactivation of Foxa2 in the 
hypothalamus, we analyzed high fat diet-induced obese mice, which provide a 
hyperinsulinemic model of type 2 diabetes.  As expected, high fat diet-induced 
Figure 56.  Insulin induces nuclear
exclusion of hypothalamic Foxa2.
Immunoblot analysis of nuclear and
cytoplasmic extracts prepared from
pooled hypothalami from 3 mice each that
were either fasted overnight or ad libitum
fed. TBP, TATA binding protein.
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obesity and the corresponding increases in plasma insulin result in constitutive 
nuclear exclusion of Foxa2 in the hypothalami of these mice.  While Foxa2 is 
completely nuclear in fasted chow fed mice, cytoplasmic levels of Foxa2 in 
hypothalmi from high fat diet-fed mice are similar to those of ad libitum fed 
controls (Figure 58).   
 
Figure 58.  Foxa2 is constitutively cytoplasmic in hypothalami from high fat diet-fed mice.  
Immunoblot analysis of nuclear and cytoplasmic extracts prepared from hypothalami of fasted, fed or 
fasted high fat diet-fed mice.  Each lane represents hypothalami pooled from 2 mice.  γ-Tubulin was 
used as a general loading control, and LSD1 (Lysine-specific demythlase 1) and GAPDH served as 
nuclear and cytoplasmic extraction controls, respectively. 
 
  
Correspondingly, expression of both MCH and orexin was decreased by 
~60% in hypothalami of fed and high fat diet-fed mice, compared to fasted 
controls (Figure 59).  Further work in the lab has shown that MCH and orexin 





Figure 59.  Real-time RT-PCR analysis of MCH and orexin in fasted, chow fed  and fasted, high fat 
diet-fed (HF) mice.  Results are expressed as amount of cDNA normalized to GSPDH cDNA. The 
values represent the mean ± sem (n=5 in all groups; *, P<0.05; **, P<0.01). 
5.3  Constitutive activation of Foxa2 in the hypothalamus 
In order to show that Foxa2 activation is sufficient to induce metabolic 
changes associated with MCH and orexin we constitutively activated Foxa2 in 
hypothalamic nuclei by 3 different means.  First, conditional mutant mice with 
a constitutively active Foxa2-T156A allele were generated by introducing loxP 
sites upstream and downstream of exon 3, which encodes most of the open 
reading frame of Foxa2 as well as the 3’ untranslated region.  An exon 3 
duplication, harboring the T156A mutation, was introduced downstream of the 
floxed wildtype exon 3 and neuron specific recombination was obtained by 
breeding to nestin-Cre mice.  These mice show significantly increased 
expression of MCH and orexin, as well as CPT1, MCAD and VLCAD, Foxa2 
target genes involved in mitochondrial β-oxidation (Figure 60).   
Accordingly, these mice show a significant enhancement of metabolic 
function.  Serum glucose levels, plasma insulin levels and serum free fatty acid 
concentrations are all decreased in the fed state in Nes-Cre/Foxa2T156Afl/fl 
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mice compared to control littermates (Figure 61).  Glucose clearance from the 
circulation following an insulin tolerance test is modestly increased in Nes-
Cre/Foxa2T156Afl/fl mice, indicating increased insulin sensitivity (Figure 61). 
 
Figure 60.  Real-time RT-PCR analysis of gene expression in mice with neuron-specific activation of 
Foxa2.  cDNA was prepared from  hypothalami of fed Nescre/+, Foxa2T156Afl/fl mice, fed 
Foxa2T156Afl/fl mice and fed Nescre/+ mice.  Relative expression of MCH, Orexin, CPT1, Mcad, and 
Vlcad was normalized to β-actin or GAPDH housekeeping genes. The results are expressed as fold-
induction over fed Foxa2T156Afl/fl mice and represent the mean ± SEM. 
 
 
Figure 61.  Altered serum parameters in Nes-Cre/Foxa2T156Afl/fl mice.  Blood glucose, percentage of 
starting plasma glucose concentration during an insulin tolerance test, plasma insulin and plasma 




Measurements of metabolic rates reveal that Nes-Cre/Foxa2T156A fl/fl 
mice have increased O2 consumption and CO2 production, and exhibit 
dramatic increases in spontaneous physical activity over 24 hours compared to 
Nes-Cre/+ and Foxa2T156A fl/fl control mice (Figure 62).  Food 
consumption and drinking volume are also increased in Nes-Cre/Foxa2T156A 
fl/fl animals (Data not shown).  
 
Figure 62.  Altered metabolic parameters in Nes-Cre/Foxa2T156A fl/fl mice.  Spontaneous physical 
activity during a light phase 12 hr interval, oxygen consumption and CO2 production were determined 
simultaneously during a 24-h period in individual mice using an oxymax metabolic chamber system. 
 
To ensure that these effects were not due to activation of Foxa2 in 
neurons outside of the hypothalamus we used two alternate methods to express 
constitutively active Foxa2 specifically in the hypothalamus:  injection of 
constitutive Foxa2-T156A adenovirus into the hypothalamus of wildtype mice, 
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and direct injection of adenovirus CRE into hypothalami of Foxa2T156A fl/fl 
mice.  Cellular fractionation confirmed the expression and constitutively 
nuclear localization of Foxa2-T156A in fed mice injected with either Ad-T156A 
or Ad-Cre, while endogenous Foxa2 is cytoplasmic (Figure 63, Figure 64).  
Both of these methods achieved similar results to the Nes-Cre/Foxa2T156A 
fl/fl experiments, demonstrating that the metabolic phenotypes are due to 
constitutive activation of Foxa2 in the hypothalamus. 
 
Figure 63.  Hypothalamic expression and localization of Foxa2 after AdT156A injection.  C57Bl/6 
mice were given hypothalamic injections of adenovirus expressing GFP or Foxa2-T156A.  
Immunoblots of cellular fractionation experiments are shown.   
 
 
Figure 64.  Hypothalamic expression and localization of Foxa2 after AdCre injection in Nes-
Cre/Foxa2T156A fl/fl mice.  Nes-Cre/Foxa2T156A fl/fl mice given hypothalamic injections of either 
GFP or Cre adenovirus.  Immunoblot analysis of nuclear and cytoplasmic fractions are shown. 
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5.4  Summary 
These studies reveal a molecular mechanism by which insulin controls 
the feeding/fasting response of the lateral hypothalamus.  In fasting conditions, 
Foxa2 acts as a direct transcriptional activator of MCH and orexin genes, 
thereby stimulating classical fasting responses such as feeding, behavioral 
arousal and spontaneous physical activity. In the fed state, Foxa2 is 
phosphorylated by insulin/PI3K/Akt signaling, which leads to Foxa2 
inactivation and nuclear exclusion.  Interestingly, MCH and orexin expression 
is regulated by the same metabolic stimuli and molecular signaling pathway, 
thereby integrating metabolic and adaptive behavioral responses.  Similar to 
what we have shown for the liver and lung, Foxa2 is permanently inactive in 
MCH and orexin neurons in hyperinsulinemic states such as type 2 diabetes, 
resulting in reduced MCH and orexin expression. Conditional constitutive 
activation of Foxa2 in the hypothalami of these mice leads to increased physical 











Affect of genetic variation on Foxa2 regulation and associated metabolic 
activity  
While data support a role for Foxa2 as a metabolic transcription factor, 
there is conflicting evidence regarding its inactivation, particularly its nuclear 
exclusion by insulin.  Our studies confirm that Foxa2 can be inactivated 
through insulin-induced nuclear exclusion in all mouse strains tested.   
However, marked differences exist in the modulation of metabolic pathways by 
insulin signaling with respect to background genetic strain differences.  The 
inherent metabolic differences in the strains studied are exemplified by their 
responses to high fat diets.  C57Bl/6 mice are generally more obese, glucose 
intolerant, and hyperinsulinemic on high fat diets and exhibit higher levels of 
liver triglycerides, increased hepatic steatosis, and insulin sensitivity than their 
129 counterparts (101) (102).   These findings are in line with our observations, 
which demonstrate that in addition or due to having lower insulin levels, Sv129 
mice have higher rates of β-oxidation and increased oxygen consumption in 
comparison to C57/B6 mice.  Accordingly, only in C57Bl/6 and dba mice were 
the postprandial levels of insulin high enough to effect nuclear exclusion of 
Foxa2 under physiological circumstances.  These data provide a plausible 
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explanation for the observed discrepancies in nuclear exclusion of Foxa2 
reported by Zhang et al (11).  
 We also demonstrate that primary hepatocytes from hyperinsulinemic 
insulin resistant mice (ob/ob, db/db and HF-diet induced obese mice) are 
capable of shuttling Foxa2 back into and out of the nucleus in culture, while 
Foxa2 is always cytoplasmic in livers of these mice in vivo.  These data 
demonstrate that hepatocytes from these mice are not defective, but accurately 
reflect the insulin concentrations to which they are exposed. 
Not only do our data demonstrate the importance of genetic background 
on metabolism and Foxa2 regulation, but we also find the inverse to be true:  
the activation state of Foxa2 is sufficient to account for some of these observed 
metabolic alterations.  While constitutive activation of Foxa2 in Sv129 mice has 
little effect (Foxa2 is already active), constitutive activation in C57Bl/6 mice 
normalizes β-oxidation between fasting and feeding states by increasing β-
oxidation in the fed state, corresponding with Foxa2-dependent activation of 
target genes such as Mcad, Vlcad and CPT1.  
The increased insulin levels in “obesity-prone” C57Bl/6 inbred mice (in 
the fed state) result in the translocation of insulin-dependent hepatic factors 
Foxo1 and Foxa2 from the nucleus, which leads to the inhibition of 
downstream target genes involved in glucose and lipid metabolism. This could 
also serve to set up a negative feedback loop whereby genetic factors in certain 
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strains lead to decreased Foxa2 activity (or to increased insulin and thereby 
decreased Foxa2 activity) , which in turn leads to decreased metabolism and 
enhanced metabolic differences between strains.  In such a case, with the 
addition of a high fat diet or additional environmental stresses, this negative 
feedback could be even further exacerbated in the “obesity-prone” mice, 
resulting in this exaggerated phenotype.  
The development of diabetes and the associated metabolic syndrome in 
humans is also dramatically affected by background genes.  In mice, this was 
first reported for the ob/ob and db/db traits (53) and has been shown 
subsequently in mice with genetically induced lipodystrophy (103), and diet-
induced obesity (104). Furthermore, a recent study showed that in the insulin 
receptor/IRS-1 double-heterozygous knockout, the background genes of 
C57/B6 mice caused severe hyperinsulinemia and diabetes, whereas 
background genes of the Sv129 strain protected against diabetes (105). This 
"thrifty" phenotype displayed by the C57/B6 mice as shown by weight gain, 
hyperinsulinemia, and increased hepatic lipid content is similar to that observed 
in various human populations that exhibit an increased susceptibility to obesity 
and diabetes, given an average caloric intake (106, 107).  Even though the 
causes of increased release of insulin are unclear, it may be possible to 
counteract some of the pathophysiological conditions that are a direct result of 
the metabolic syndrome.  Thus, it is of the utmost interest to elucidate ways to 
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modulate Foxa2 activity through dephosphorylation and nuclear reactivation, 
with the goal of influencing hepatic lipid metabolism and thereby alleviating 
symptoms such as hepatic steatosis and insulin resistance. 
 
Inhibition of Foxa2 occurs independently of nuclear exclusion 
Previous data from our lab provide evidence for a strong correlation 
between insulin signaling, T156 phosphorylation, nuclear exclusion and 
inactivation of Foxa2 (10, 36).  While nuclear exclusion certainly leads to 
inhibition of transcriptional activity, there was previously no means to 
differentiate between these correlative observations. The novel identification of 
a functional NES in Foxa2 has now allowed us to uncouple these events.   
Interestingly, alignment of the Foxa2 NES shows that it is well-
conserved throughout vertebrate homologues of Foxa2.  Minor variations 
within the sequence occur from Xenopus to human (methionines instead of 
leucines at amino acids 110 and 113), but these changes conserve the overall 
character of the export sequence and are not likely to hinder nuclear export 
capability.  Indeed, it has been shown that hydrophobic residues other than 
leucine (including isoleucine, valine, methionine, and phenylalanine) may 
constitute a functional CRM1 NES (62, 108). By contrast, this sequence 
conservation does not extend to Fork head, the Drosophila homolog of Foxa2.  
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Consequently, Drosophila Fork head may not be capable of shuttling in response 
to insulin stimulation, suggesting that the nuclear export capability may have 
arisen later in evolution.  Notably, the T156 phosphorylation site (T207 in 
Drosophila) is conserved (36).  It will therefore be interesting to see whether the 
same mechanism of insulin-induced phosphorylation exists in flies, and 
whether this also results in Fork head inactivation. 
Mechanisms to this effect have also been reported for the Foxo family 
of transcription factors.  Phosphorylation of three critical residues in Foxo1 has 
been shown to contribute to nuclear export and subsequent loss of 
transcriptional activity in response to insulin/IGF signaling (46, 47, 58).  In vitro 
data suggest that Serine 256 acts as a “gatekeeper” to subsequent regulatory 
events, with phosphorylation at this residue resulting in transcriptional 
inhibition of nuclear Foxo1 (50, 109).   However, additional posttranscriptional 
modifications have also been shown to contribute to the regulation of FoxO 
family members, including acetylation, ubiquitination and methylation 
(reviewed in (110, 111).  The relative contribution and exact mechanisms of 
these modifications are still being worked out. 
Our data support a model whereby phosphorylation of Foxa2 acts as the 
dominant signal for transcriptional inactivation; however we cannot exclude the 
possibility that additional post-translational modifications exist.  Since we 
generally observe that Foxa2 runs about 9 kDa above its predicted molecular 
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weight, we asked whether it might be sumoylated or ubiquitinated.  Running 
the rat Foxa2 amino acid sequence through a sumoylation site predicting 
program identified several sites with high probability, and several with low 
probability (Figure 65).  Intriguingly, one of the high probability sites is very 
close to the Akt phosphorylation site.   
 
Figure 65.  Sumoylation site prediction.  The amino acid sequence for rat Foxa2 was put into 
SumoPlot, a sumoylation prediction program.  The following high and low probability sites were 
predicted.  The Foxa2 Akt phosphorylation site is shown in green, for reference. 
 
To test whether Foxa2 is sumoylated we used whole cell lysates from 
insulin-treated primary hepatocytes infected with the four Foxa2 variant 
viruses.  Surprisingly, we observe a very strong sumoylation signal in 
immunoprecipitates, and even in whole cell lysates of all insulin-stimulated 
primary hepatocytes, except GFP controls (Figure 66).  There did not seem to 
be any difference in sumoylation state between the viruses however, and more 
data will need to be acquired to determine the function of Foxa2 sumoylation, 




Figure 66.  Foxa2 is sumoylated.  Primary hepatocytes were infected with the indicated adenovirus, 
serum starved overnight and stimulated with 100nM insulin for 15 min.  Whole cell lysates were then 
saved as input, or immunoprecipitated (IP) with an anti-HA antibody.  Immunoblots of input and IPs 
were probed with an antibody against SUMO1. 
 
  In an attempt to determine whether the phosphorylation site is 
sufficient to induce inactivation of Foxa2 we generated Foxa2-T156E or -
T156D phosphomimetic variants.  These both appear to result in constitutively 
nuclear Foxa2 when stably expressed in HepG2 cells, although further studies 
are needed to sufficiently assay its activation state (data not shown).  Thus, 
whether this single phosphorylation event is sufficient for inactivation of Foxa2 
remains to be determined.   
One plausible hypothesis for the regulation of Foxa2 by 
phosphorylation, is that T156 phosphorylation, which occurs N-terminal of the 
DNA binding domain, directly decreases the DNA binding affinity of Foxa2.  
While EMSA data suggest that this is not the case, it was not possible to 
monitor the phosphorylation state of Foxa2 in these assays (36).   Alternatively, 
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or additionally, phosphorylation (or other modifications) could affect 
coactivator or histone binding.    
Our data thus provide a novel perspective on the regulation of Foxa2 by 
insulin, which can potentially be applied to the hormonal regulation of other 
transcription factors.  Additionally, the discovery of an essential NES 
controlling insulin-induced nuclear export of Foxa2 lays a strong foundation 
for the identification of additional signaling pathways and/or post-translational 
modifications involved in the regulation of Foxa2 activity. 
The constitutive inactivation of Foxa2 by insulin, in addition to the 
beneficial effects of constitutively active Foxa2 in mouse models of obesity 
make understanding the molecular mechanisms of its regulation of great 
scientific, and potentially therapeutic interest.  Taken together, our data show 
that Foxa2 is subject to active nuclear export in response to insulin signaling, 
that this export is not prerequisite for transcriptional inactivation and that 
Foxa2 phosphorylation is the most direct readout of Foxa2 activity. 
 
Pulmonary and embryonic regulation of Foxa2 by insulin 
We clearly observe insulin-induced nuclear exclusion of Foxa2 in lung 
cells, just as has been previously described for hepatocytes.  Expression of 
Foxa2 is enriched in lung, as it is in liver, so to some degree it is not surprising 
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that it behaves similarly in both tissues.  Curiously, though, there is no well 
established metabolic reason for gene expression in lung tissue to be regulated 
by the routine insulin fluctuations that accompany fasted and fed states.   
We hypothesize that an indirect connection between insulin and 
metabolism may be found in the production of lung surfactant proteins.  Lung 
surfactant maximizes the surface area of the lung available for gas exchange, 
and therefore expression of surfactant genes may increase the efficiency of 
respiration.  Efficient respiration, in turn, may permit more efficient use of 
energy during periods of activity, and studies have shown that caloric 
restriction stimulates locomotion.  Indeed, in chapter 5 we report the novel 
regulation of Foxa2 by insulin in the hypothalamus, where nuclear Foxa2 
(induced by fasting), increases locomotion and food-seeking behavior.  In this 
way, insulin-dependent regulation of Foxa2 in the lung may correlate with the 
overall metabolic state of the organism.  This model would also implicate 
Foxa2 in one of the developmental disorders associated with type 2 diabetes:  
impaired lung function in infants of mothers with uncontrolled gestational 
diabetes (84, 85).  These mothers are generally hyperinsulinemic, but insulin 
resistant and therefore hyperglycemic.  While insulin does not cross the 
placenta, glucose does, and an excess of blood glucose stimulates the fetal 
pancreas to produce more insulin, thus rendering the fetus hyperinsulinemic. 
We hypothesize that this results in the cytoplasmic localization and inactivation 
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of Foxa2 in the lungs of fetuses developing in insulin resistant mothers, leading 
to reduced surfactant production just prior to their transition to air breathing at 
birth.  There is also some evidence for an associated risk of respiratory diseases 
like asthma and chronic obstructive pulmonary disease in adults with obesity 
and type II diabetes (80-82). 
The most obvious way for Foxa2 to regulate surfactant production is 
through transcriptional control of surfactant genes.  Surfactant protein B (SP-
B) and clara cell secretory protein (CCSP) are both reported Foxa2 target genes 
in the lung (76, 112), however our initial realtime PCR analysis for fasted and 
fed adult lung show very minor, if any, changes in these genes.  Interestingly, a 
different surfactant protein, SP-A, was significantly decreased.  Furthermore, 
several genes from our microarray analysis on embryonic lung look promising 
in terms of being potential Foxa2 targets that are also implicated in lung 
function:  Reg3g, Scgb3a1, and muc5b.  While these genes do not encode 
surfactant proteins per se, they are all implicated in host defense, suggesting a 
possible alternative or additive function for insulin sensitivity in the lung.  
Our observations do not preclude the possibility of surfactant regulation 
by Foxa2 in a more indirect manner or on a longer timescale.  Indeed, the fact 
that Foxa2 is expressed in lung and is regulated by insulin strongly suggests that 
it mediates some metabolic regulation of this organ.  Further study is required 
to more fully investigate the possibility of insulin-dependent regulation in lung 
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tissue, and to understand the molecular mechanisms responsible for diabetes-
associated lung disorders. 
Finally, our studies demonstrate that Foxa2 target genes in the liver can 
be disregulated by insulin signaling during development, as early as E19.  The 
long term effects of this early disregulation are not known, however it is 
possible that it starts the negative feedback loop discussed earlier, and so sets 
the stage for insulin resistance or obesity later in life.  If so, this would be 
relevant to human forms of the disease which can be “inherited” but are not 
always directly linked to genetics. 
Regulation of Foxa2 in the Hypothalamus 
A well established connection has been noted between the neurons of 
the lateral hypothalamus and feeding behavior or arousal (113-116).  For 
instance, trauma to the LHA may result in decreased arousal, failure to meet 
metabolic challenges by modifications in behavior, and ultimately death by 
starvation (117, 118).  Our studies elucidate a molecular mechanism through 
which metabolic state may influence behavioral responses:  insuilin-dependent 
signaling in the lateral hypothalamus inhibits Foxa2-dependent expression of 
MCH and orexin neuropeptides.   
As observed in the liver, Foxa2 in MCH and orexin neurons is nuclear 
and active in fasted C57Bl/6 mice, but inactive in fed C57Bl/6 mice and fasted, 
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hyperinsulinemic obese mice.  We have identified MCH and orexin as novel 
targets of Foxa2, and show that their expression is reduced when Foxa2 is 
inactivated through insulin signaling.  MCH and orexin are known to regulate 
food intake and movement, respectively (114, 116, 119, 120).  MCH increases 
food consumption, and gene deletion causes hypophagia.  Interestingly, 
increased expression of MCH on its own results in obesity in susceptible mice; 
however increased expression of MCH in Nescre/+,Foxa2T156Afl/fl mice did 
not have this effect.  This can be attributed to the coregulation of orexin, which 
mediates wakefulness and results in increased activity.  Orexin gene deletion is 
associated with narcolepsy and obesity.    As MCH and orexin signaling are 
associated with activity and feeding behavior, their downregulation in this 
hyperinsulemic model may constitute a system of negative feedback, which 
exacerbates the phenotype.  Indeed, decreased activity is a common 
phenomenon overweight individuals, in humans and in mice, and is now 
recognized as a major factor contributing to the continuing rise in obesity. 
Interestingly, introduction of constitutively active Foxa2-T156A in these 
mice leads to improved metabolic properties, including ameliorated glucose 
homeostasis, decreased fat and lean body mass, and increased physical activity.  
These observations suggest that Foxa2 activation in the hypothalamus may be a 





Materials.  Human recombinant insulin (I9278), Collagen (Type I, C3867), 
phosphate-buffered saline pH 7.4 (PBS) and Leptomycin B (L2913) were 
purchased from Sigma.  HALT phosphatase inhibitor cocktail was from Pierce, 
and Complete protease inhibitor cocktail was from Roche.  Antibodies to: HA 
(Covance and Santa Cruz), Foxa1 (a gift from J. Darnell, Rockefeller 
University; or from Abcam, ab23738), rabbit or goat polyclonal to Foxa2 
(Abcam), phosphorylated Foxa2 (T156) antibody was generated and described 
previously (Cell Signaling) (10), LSD1 (Cell Signaling), GAPDH (Abcam), 
Orexin A (Abcam, ab35337), pro-MCH (Santa Cruz, sc-14509) gamma tubulin 
(Sigma), AKT (Cell Signaling), Foxo1 (Santa Cruz), TAF100 (a gift from R.G. 
Roeder, Rockefeller University), SUMO-1 (Zymed, 38-1900).   
 
Animal Models.   C57BL/6 and ob/ob mice were purchased from Charles 
River.  All animals were maintained on a normal chow diet and a 12 h 
light/dark cycle.  All mutant animals were crossed to a C57Bl/6 background.  
Diet induced obese animals were fed a high fat diet (Harland Teklad) 
containing 50% fat for 12 weeks.  Gestation was dated by detection of the 
vaginal plug, which was considered gestational/embryonic day 1.  
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Sreptozotocin-induced diabetes was initiated on gestational day 14; mice were 
given 3 injections of 75 mg/kg stz over 3 days. 
 
Generation of FOXA2 T156A knock-in mice.  FOXA2T156Afllox/flox mice 
were generated using a targeting construct.  The short arm spanning exon 1 and 
2 (3.4 kb in length) from bp position -2517 to +919, relative to the translation 
start site (+1). The long arm, which contained exon 3 with the T156A mutation 
was 4.7 kb in length from bp position +1034 to +5782, relative to the 
translation start site.  Wild type exon 3 was located between the long and short 
arm and flanked by a loxP sequence.  A neo/tk cassette, flanked by loxP sites, 
was inserted upstream of wild type exon 3. An outside probe was used to 
visualize homologous recombination and Cre recombination events. The 
targeting vector was electroporated into R1 ES cells from mouse strain 129 
(Nagy et al., 1993) and neomycin-resistant colonies were recovered. The 
colonies were screened by Southern blotting using probe 1 and positive 
colonies were confirmed by Southern blotting with a probe located 
downstream of the 3’ homology arm. To delete the neo/tk-cassette from the 
targeted allele, recombinant ES clones were transiently transfected with a 
plasmid expressing Cre-recombinase. ES clones with partial recombination and 
deletion of the neo/tk cassette were injected into B6(D2B6F1) blastocysts to 
produce chimeric mice. Germline transmission was confirmed by Southern 
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blotting.  FOXA2T156Aflox/flox mice were first backcrossed for 7 generations to 
C57Bl/6J mice. To obtain brain-specific FOXA2T156A knock-in mice, 
FOXA2T156Aflox/flox mice were bred to Nestin-Cre mice (B6.Cg-Tg(Nes-
cre)1Kln/J, Jackson Laboratories) (14), which had been backcrossed to 
C57Bl/6J for at least 6 generations. To confirm expression of the Foxa2T156A 
allele, Foxa2T156A transcripts were amplified from brain and liver using 
primers spanning one intron of the mouse Foxa2 gene 
(AGCGGCCAGCGAGTTAAAGTATGC and 
CTGCCGGTAGAAAGGGAAGAGGTC).  RT-PCR products were cloned 
into the TOPO3 vector (Invitrogen) and sequenced. 
 
Plasmids and Adenovirus. HA-tagged Foxa2, Foxa2-T156A, and Akt2 were 
in PCDNA3 expression vectors as previously described (36).  Emut (L110A, 
L113A) and TAE (L110A, L113A, T156A) constructs were generated by site-
directed mutagenesis using overlap extension PCR.  Adenoviruses were 
generated using the Rapid Adenovirus Production System (Viraquest). With the 
exception of Ad-GFP-C1Foxa2, GFP was coexpressed from an independent 
promoter in addition to HA-Foxa2 or Foxa2 variants. Ad-GFP, Ad–Foxa2 and 
Ad–T156A were described previously (10). For in vivo experiments, mice were 




Cell culture.  HepG2 cells and primary hepatocytes were maintained on 
collagen-coated plates in DMEM (Gibco, containing 4.5 g/L glucose, 110 
mg/L sodium pyruvate, 4 mM L-glutamine) supplemented with 10% fetal 
bovine serum (Sigma) and 100 U/mL penicillin/ streptomycin, in a humidified 
incubator at 37°C and 5% CO2.  Serum starvation was carried out for 18 h in 
DMEM without FBS and Pen/Strep.  Stable cell lines were generated by 
transfection of 4.5x106 HepG2 cells with 6 μg of plasmid DNA using Fugene6 
transfection reagent (Roche), and selection with 1 mg/mL of G418 
(Calbiochem) over 2-3 weeks.  Clonal populations were isolated and analyzed 
for expression of Foxa2 constructs by western blotting using an anti-HA 
antibody (MMS-101P, Covance).  
 
Primary Hepatocytes.  Mice were anesthetized with pentobarbital. A catheter 
(24 gauge) was inserted into the portal vein, and the liver was perfused with a 
buffer containing 10 mM HEPES (pH 7.4), 143 mM NaCl, 7 mM KCl, and 0.2 
mM EDTA at a flow rate of 1 ml/min. Effluent exited via the vena cava 
inferior. After 10 ml of perfusion, the buffer was switched to a collagenase 
buffer (50 mM HEPES (pH 7.4), 100 mM NaCl, 7mM KCl, 5mM CaCl2, and 
0.2% collagenase type IV (Sigma)). After 6 ml of perfusion, the liver was cut 
out and minced in Dulbecco’s modified Eagle’s medium (with 10% fetal bovine 
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serum) containing 4.5 g/liter glucose.  Hepatocytes were released from the liver 
during 15 min of light shaking at 37 °C.  The cell suspension was filtered 
through a 40 μm nylon mesh cell strainer (BD Falcon) and centrifuged at 80 x g 
to pellet the hepatocytes.  The cell pellet was washed three times with warm 
media, and the cells were plated onto collagenized plates. Cells were allowed to 
attach for 6 h after which cells were washed and medium was changed. 
 
Whole Cell Extracts.  From HepG2 cells:  Cells were washed, scraped and 
centrifuged at 500 x g for 5 m at 4°C in cold 0.01 M PBS.  The cell pellet was 
then resuspended in whole cell extract buffer (150 mM NaCl, 50 mM Tris pH 
7.4, 5 mM EDTA, 0.1% SDS, and complete protease inhibitor (Roche)).  The 
soluble fraction was collected after centrifugation at 13,000 rpm for 5 m at 4°C.  
A two-step lysis was used for tissue whole cell extracts:  tissues were dounced 
10-15x with a tight pestle in cold buffer A (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.6% NP40) containing 1.67x phosphatase inhibitor 
cocktail (Pierece HALT) and 1.67x protease inhibitor cocktail (Complete 
mixture Roche Applied Science) and incubated on ice for 10 m.  Lysates were 
then vortexed for 5 s, followed by dropwise addition of 140 μL of buffer B (1.2 
M NaCl, 20 mM Hepes pH 7.9, 0.2 mM EDTA, 1.5 mM MgCl2, 25% 
glycerol;without additives) and overhead rotation for 40 m at 4°C to ensure 
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lysis.  Insoluble cellular components were removed by centrifugation at 16,000 
x g for 30 m at 4°C, and the supernatant was collected. 
 
Protein measurement.  In all cases, protein concentrations were determined 
bicinchoninic acid (BCA) assay using a bovine serum albumin standard curve 
prepared in the cell lysate buffer.  (In the case of buffers containing DTT the 
standard curves were always made fresh for most accurate quantitation). 
 
Nuclear Fractionation.  Initial nuclear extraction experiments were by 
sucrose gradient fractionation.  Tissues were dounced 20x in homogenization 
buffer (10 mM Hepes pH 7.9, 25 mM KCl, 2 M Sucrose, 10% glycerol, 1 mM 
EDTA) containing protease inhibitor cocktail (added fresh).  Homogenates 
were carefully layered over a 1 cm cushion of homogenization buffer in SW55 
ultracentrifugation tubes (Beckman) and centrifuged at 100,000 x g (29,000 
RPM in SW55) for 40 minutes at 4°C.  Supernatant was carefully removed by 
pipetting and discarded, and nuclear pellets were resuspended in 2 mL of 
nuclear lysis buffer (10 mM Hepes pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1 
mM EDTA) containing 1 mM DTT and protease inhibitor cocktail (added 
fresh).  Nuclear lysates were incubated on ice for 20 minutes, followed by the 
addition of 0.1 volume (NH4)2SO4 over 30 m to precipitate chromatin, and 
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centrifuged at 100,000xg (29,000 RPM) for 60 min at 4°C.  The supernatant 
was collected and 0.66 g of (NH4)2SO4 was added  over 15 m to precipitate 
protein, which was pelletted by centrifugation for 30 minutes at 100,000g at 
4°C and resuspended in nuclear resuspension buffer (25 mM Hepes pH 7.4, 40 
mM KCl, 0.1 mM EDTA, 10% (v/v) glycerol) containing 1mM dTT (added 
fresh).  Protein was dialyzed overnight against 3 x 2 L of nuclear resuspension 
buffer. 
 
Nuclear/Cytosoplasmic Extracts.   HepG2 cells were grown in 10 cm plates 
to 80% confluency and serum-starved for 18 h, followed by the indicated 
treatments (LMB: 2 h with 2.5 ng/mL leptomycin B, Insulin: 500 nM human 
recombinant insulin for 15 min at 37°C).  Nuclear and cytoplasmic extracts 
were prepared as previously described (23).  Briefly, cells were swollen on ice in 
hypotonic lysis buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl) 
containing 1 mM dithiothreitol and protease inhibitors (Complete mixture, 
Roche Applied Science), and permeabilized by the addition of NP40 to 0.6%.  
After centrifugation at 10,400xg for 30 sec at 4°C, the supernatants 
(cytoplasmic extracts) were collected, and nuclear pellets were resuspended in 
nuclear lysis buffer (10 mM HEPES pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1 
mM EDTA) containing 1 mM dithiothreitol and protease inhibitors.  Nuclei 
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were lysed by the gradual addition of one-tenth volume of 4 M (NH4)2SO4 over 
30 min.  For liver experiments, ~50 mg of liver was dounced directly in 
hypotonic lysis buffer on ice, 10x with a tight pestle.   
 
Quantification of Cytosolic and Nuclear Foxa2.  Western blots were 
scanned and band intensity quantified by densitometry using Kodak imaging 
software. Each value was normalized to the corresponding γ-tubulin value. To 
account for differences in blotting and exposure, each blot contained the same 
standard, and all values were adjusted to the intensity measured for this 
standard. 
 
Transfection and Transactivation assays.  HepG2 cells were plated at 
70,000 cells per well in 24-well plates and transfected the following day with 25 
ng p6xCdx-TkLuc reporter gene (36), 10 ng pRL-Tk, and 25 ng of Foxa2 
expression vectors alone or in combination with 5 ng of a human Akt2 
expression vector using Lipofectamine 2000 (Invitrogen).  Cells were harvested 
40 h post-transfection and luciferase was measured using the Dual Luciferase 





Immunofluorescence Microscopy.  Liver pieces were frozen directly in OCT 
(optimal cutting temperature) compound at –80°C.  9 μM cryosections were 
fixed in 4% paraformaldehyde in 0.01 M PBS at 4°C for 30 min, permeabilized 
in 0.2% NP40 in PBS, blocked in 5% NDS, 1% BSA, 0.1% NP40 in PBS, and 
incubated with anti-HA antibody (1:25, Santa Cruz Biotechnology, sc-805) 
overnight at 4°C in a humidified chamber.  Donkey anti-rabbit IgG Alexa Fluor 
488 (Molecular Probes) was used as a secondary antibody, and mounted with 
VECTASHIELD mounting media with Dapi (Vector Labs) to visualize nuclei.  
For hypothalamus staining, mice were CO2-anesthesized and intracardially 
perfused with 5 ml of phosphate-buffered 2% paraformaldehyde (pH 7.4). 
Brains were postfixed in phosphate-buffered 2% paraformaldehyde (pH 7.4) 
for 10 minutes at room temperature, equilibrated in phosphate-buffered 30% 
sucrose at + 4O C for 24 hours and frozen in tissue-tek OCT compound 
(Sakura). Brains were cryo-sectioned into 12μm thick coronal sections, which 
were stored at -20 °C until further use. Cryosections were permeabilized for 1 h 
at room temperature in 10mM PBST (10 mM PBS, pH 7.4, 0.1%-Triton X-
100), blocked with 1% BSA, 5% serum in PBST for 1 h at room temperature 
and incubated overnight at 4 °C with the primary antibody at a 1:50 - 1:300 
dilution in 1% BSA, 5% serum in PBST. After three washes, sections were 
incubated for 1 h at room temperature with secondary antibodies (Alexa Fluor 
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488 or Alexa Fluor 568 conjugated; Molecular Probes, Invitrogen) diluted 1:500 
in 1% BSA, PBST.  Immunofluorescent staining was visualized with a Leica 
confocal microscope at 40x magnification.   
 
Immunoprecipitation.  Primary hepatocytes from three wildtype C57Bl/6 
mice were pooled and plated onto ten 10 cm collagen-treated plates.  Cells were 
washed extensively and allowed to recover over 48 h, after which they were 
infected with 2.5x107 PFU of the indicated virus.  After an additional 24 h, cells 
were serum-starved overnight, followed by 15 min stimulation in the absence 
or presence of 100 nM insulin.  Cells were washed twice in cold 0.01 M PBS 
(containing 10mM NaF, and 0.5X HALT phosphatase inhibitor cocktail from 
Pierce) and moved directly to ice, scraped and centrifuged at 500 x g for 5 m at 
4°C.  Cell pellet was resuspended in 200 μL of buffer A (10 mM HEPES pH 
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.6% NP40) containing 1.67x phosphatase 
inhibitor cocktail (Pierece HALT) and 1.67x protease inhibitor cocktail 
(Complete mixture Roche Applied Science).  Incubated cells on ice for 10 m, 
vortexed 5 s, followed by dropwise addition of 140 μL buffer B (1.2 M NaCl, 
20 mM Hepes pH 7.9, 0.2 mM EDTA, 1.5 mM MgCl2, 25% glycerol) without 
additives.  Rotated (overhead) 40 m at 4°C to ensure lysis.  Centrifuged at 
16,000 x g for 30 m at 4°C to pellet chromatin and debris, and collected 
supernatant as whole cell lysate.  Brought 120ug of protein lysate up to 276 μL 
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with A/B lysis buffer (mixed 1.5:1), added 600 μL IP buffer (0.01 M PBS pH 
7.4, .01 mM EDTA, 0.02% NP40) containing phoshpatase and protease 
inhibitor) to each and subjected all to immunoprecipitation overnight at 4°C 
with monoclonal HA agarose (Sigma A2095) in SigmaPrep spin columns.   
Washed 5 x  800 μL with IP buffer containing 10 mM NaF.  Centrifuged 1 m 
at 1000xg to remove excess liquid, plugged columns and added 60 μL 1X laemli 
buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1 mM bromophenol blue) 
to elute.  
 
Chromatin Immunoprecipitation.  Primary hepatocytes from three wildtype 
C57Bl/6 mice were pooled and plated onto ten 10 cm collagen-treated plates.  
Cells were washed extensively and allowed to recover over 48 h, after which 
they were infected with 2.5x107 PFU of the indicated virus.  After an additional 
24 h, cells were serum-starved overnight, followed by 15 min stimulation in the 
absence or presence of 100 nM insulin.  11X fixing solution (50mM Hepes-
KOH pH 7.5, 100mM NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA p H8.0, 11% 
formaldehyde) was added to the cells to a final concentration of 1X and 
incubated for 10 min at 37°C.  Cells were then moved to ice, washed twice with 
ice cold 0.01 M PBS and scraped in 1 mL ChIP cell lysis buffer (10 mM Tris–
Cl, pH 8.0, 10 mM NaCl, 1.5 mM MgCl2, 0.2% NP-40, with protease 
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inhibitors).  Lysates were centrifuged for 5 min at 5400xg at 4°C.  Pellets were 
resuspended in 450 μL of SDS Lysis buffer (Upstate Biotechnology) and 
sonicated 4x20 sec on, 30 sec off, at amplitude 16 on a Misonix Sonicator 4000.  
Lysates were further processed according to the manufacturers protocol 
(Chromatin immunoprecipitation assay kit, Upstate Biotechnology).  DNA 
complexes were immunoprecipitated overnight using 2.6 μg of HA-antibody 
(Santa Cruz Biotechnology, sc-805) or rabbit IgG (ChromPure, Jackson 
ImmunoResearch).  Primer sequences are given in Table 5. 
Table 4.  Primer Sequences and annealing temperatures for ChIP. 
Primer 
Name 
Forward Sequence Reverse Sequence Ta 
(°C) 
CPT1α AAGGCATACATCACCACAACCAGT TTCACAACAACACTGTGGTGTGC 57
Gck TCTCCACACCAGCTTGGAACC TTTCACCACCATCAGTATGCAC 57
HMGCS1 TGCACTGTTCCTGGCTGGTATCTA TGATTGTTGGATGTGTTAGAAGGA 57
LPK TCTCTATTGAAGCTGATGGACTG AGTCCCCACATCTTCCCTTCC 57
PEPCK ATACGTACATACTGACCCCTGCTC GATCATCAGAGTTCCATTTCAAGA 57
 
Gene Chip.  Adult lung RNA was prepared from 5 fasted and 5 fed mice by 
Trizol extraction, pooled and purified using RNEasy columns (Qiagen).  RNA 
was then submitted to the functional genomics center (ETH Zurich) for 
labeling and hybridization.  Whole snap-frozen embryonic lungs from two 
fetuses of stz-induced diabetic mothers, and two from fasted mothers were 
submitted to Miltenyi for RNA extraction, labeling, and hybridization onto a 





Gene Expression.  Total RNA was extracted from lung tissue using TRIzol 
reagents following the manufacturer’s instructions (Invitrogen).  Contaminating 
genomic DNA was removed by a 3 hour DNase I treatment (Ambion).  RNA 
quality was confirmed by denaturing gel electrophoresis stained with ethidium 
bromide. cDNA was synthesized using Superscript III with random hexamer 
primers and oligo dT according to the manufacturer’s protocol (Invitrogen).  
Combined extraction of mRNA and cDNA synthesis were performed from 50 
mg of liver tissue with the μMACS One-step cDNA Kit (Miltenyi Biotec) 
following the manufacturer's protocol, with an additional 10 minute RNase-free 
DNase I treatment (NEB).  Gene expression was measured quantitatively as a 
function of SYBR green incorporation during PCR using gene-specific exon-
spanning primers, LightCycler 480 SYBR Green I Master mix (Roche) and the 
Mx3005P Real-Time QPCR Detection System (Stratagene).   Values shown are 
given in arbitrary units based on a standard curve, and normalized to GAPDH.  








Table 5.  Primer sequences and annealing temperatures for real-time PCR. 
Primer 
Name 
Forward Sequence Reverse Sequence Ta
°C
Apq3 GCTGGGATTGTTTTTGGGCTGTAC GCGGCTGTGCCTATGAACTGATC 63
CCSP TCACTGTGGTCATGCTGTCCATCT TGAAAGGCTTCAGGGATGCCACAT 63
CPT1α AGCGACTCTTCAATACTTCCCGCA TCTGTGGTACACGACAATGTGCCT 63
Foxa2  AAGTATGCTGGGAGCCGTGAAGAT CGCGGACATGCTCATGTATGTGTT 60
GAPDH CTGACGTGCCGCCTGGAGAAA CCGGCATCGAAGGTGGAAGA 63
HMGCS1 AATCCAGCTCTTGGGATGGACGAT ACCTGTAGGTCTGGCATTTCCTGT 63
MCAD AGTACCCGTTCCCTCTCATCAA TACACCCATACGCCAACTCTTC 60
SP-A TGCACCTGGAGAACATGGAGACAA ATGGATCCTTGCAAGCTGAGGACT 63
SP-B CCTGCCCCTGGTTATTGACTACTTC GCAGCACAGGGAGGACCAG 63
SP-C CGCCTTCTCATCGTGGTTGT AGGAGCCGCTGGTAGTCATA 63
VLCAD GGTTACCCATGGGCTCCCTGAAAAG TTGAAGCCATCTCCCACCTCTCCTA 60
Orexin CTGCCGTCTCTACGAACTGTTG CGCTTTCCCAGAGTCAGGATA 60
MCH TTCAGAAGGAAGATACTGCAGAAAGA CGCTCTCGTCGTTTTTGTATTG 60
β-actin GAGAAGCTGTGCTATGTTGCTC AGGAAGAGGATGCGGCA 60
 
Immunoblotting.  Protein extracts were separated by SDS-PAGE (10%) and 
transferred onto nitrocellulose membranes (Perkin Elmer) by electroblotting. 
Membranes were immunoblotted according to standard protocols using 5% 
non-fat dry milk in TBST.  Blots were stained with Ponceau S to ensure equal 
loading and incubated with primary antibodies overnight at 4 °C (rabbit anti-
HA 1:500; rabbit anti-Foxa2 (Abcam) 1:10,000; all others were at 1:1000).  
Secondary antibody was added for 1 h at room temperature (1:10,000; 
Calbiochem). 
 
Antibody Production.  Rabbit polyclonal antibody to Foxa2 was generated by 





Physiological measurements.  Retro-orbital blood samples were taken into 
non-heparinized capillary tubes.  Blood glucose was measured using a standard 
glucometer (Ascensia Contour, Bayer).  Plasma insulin was measured with the 
Sensitive Rat Insulin RIA kit (Linco Research).  Liver triglycerides were 
extracted by the Folch method and quantitated by colorimetric assay (Roche).  
Plasma cholesterol and plasma triglycerides were measured by colorometric 
assay (Roche). 
 
Metabolic Measurements.  Locomotion (x-, y- and z-axis), food and water 
intake, oxygen consumption, CO2 and heat production were simultaneously 
determined for four mice in separate cages per experiment during a 24 h period 
in an Oxymax metabolic chamber system (Columbus Instruments) at the ages 
of 4 and 8 weeks. 
 
Mitochondrial isolation.  Mitochondria were isolated as previously described 
(121).  200 mg of PBS-perfused mouse livers were dounced in 4 volumes of 
MSM buffer (220 mM mannitol, 70 mM sucrose, 5 mM Mops pH 7.4) 4 x with 
a loose pestle.  The homogenate was diluted with MSM buffer to a final tissue 
concentration of 10% , and EDTA was added to 2 mM.  Nuclei, unbroken 
cells, and cell debris were removed by differential centrifugation at 400 x g for 
10 m.  Mitochondria were isolated from the supernatant by additional 
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centrifugation at 7000 x g for 10 m and washed once with MSM buffer.  
Mitochondrial pellets were resuspended in a small volume (20 μL) MSM buffer, 
and normalized to protein concentration.   
 
Beta Oxidation/Ketone Body Formation.  We assessed the β-oxidation of 
and ketone body production from [1-14C]palmitic acid by liver mitochondria in 
samples normalized to mitochondrial protein, as described (122).  1 mg of 
mitochondrial protein was brought up to 360 μL with preincubation medium 
(70 mM sucrose, 43 mM KCl, 3.6 mM MgCl2, 7.2 mM KH2PO4, 36 mM Tris-
HCl pH 7.4, 0.2 mM adenosine triphosphate, 50 μM L-carnitine, 15 μM 
CoASH) and incubated for 5 m at 37 °C.  40 μL of incubation media (400 μM 
[1-14C]palmitic acid (0.4 μCi/40 μL), 2.5 mg/mL BSA) was then added  and 
tubes were closed with Whatman paper-lined caps soaked in 100 mM NaOH 
and incubated for 30 m at 37 °C with in a water bath shaking at 85 RPM.  The 
reaction was stopped by adding 100 μL of 5% perchloric acid to the incubation 
mixture, and further incubated for 60 m at 37 °C with gentle shaking.  CO2 
trapped on the filter papers was counted for 14C activity by scintillation counter.  
To measure ketone body formation, the incubation mixture was centrifuged at 
4,000xg for 10min, and 14C acid-soluble products of mitochondrial palmitate 




Statistical Analysis.   Results are given as mean ± SEM, if not otherwise 
indicated. Statistical analyses were carried out by using a two-tailed Student’s 
unpaired t test, and the null hypothesis was rejected at the 0.05 level. *, p <.05; 
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